annual report positive latestage clinical study keep pace emerge new collaboration result investigational market growth aim strategic partnership establish medicine ocrelizumab multiple increase representation foundation medicine help sclerosis hope people live people establish drive innovation provide disease need develop region experience new possibility treatment option key leadership position improve patient carecontent overview highlight chairman shareholder letter ceo shareholder letter business review annual performance market environment diagnostic sale performance transform laboratory practice pharmaceutical sale performance key regulatory milestone innovation overview personalise cancer immunotherapy pharmaceutical pipeline newsflow access healthcare countryspecific access plan innovative pricing access model cover responsible business apply innovative cell culture method christoph patsch phd laboratory head culture compliance roche innovation center basel recreate human disease dish patientspecific cell manage opportunity risk provide valuable model study underlie disease biology ultimately identify novel put patient safety drug target therapeutic approach people expand diversity inclusion commit leadership environment community safety security health environment philanthropic engagement corporate governance report board director corporate executive committee remuneration report principle remuneration componentsroche roche innovation dna world large biotech company develop work breakthrough medicine improve standard biotech oncology vitro ofcare oncology immunology infectious diagnostic hospital market discipline geographie disease ophthalmology neuroscience world leader vitro diagnostic drive scientific discovery business track record allow build last redefine possible meaningful partnership world roche medicine research academia public healthcare institution essential medicine list improve patient live found family continue hold majority work understanding disease stake company stability allow differ molecular level develop tradition sustainable thinking learn new test medicine prevent diagnose setback focus last value patient employee country treat disease matter bring society remain dedicated high patient need combined strength standard quality safety integrity legacy diagnostic pharmaceutical personalise base respect individual chf healthcare strategy aim fit right treatment community world live right patient group sale roche roche focus patient excellence science personalise healthcare disease awareness treatment product portfolio strategy pipeline strategy education patent policy personalise healthcare patient organisation support datum transparency clinical trial detail pharmaceutical diagnostic drug efficacy safety counterfeiting detail innovation responsible innovation chapter biosimilar safety business chapter detail pharmaceutical diagnostic hat access healthcare responsible business chapter access healthcare great workplace sustainable value researchbase conduct materiality analysis global healthcare company corporate level key stakeholder map important topic relate combined strength priority pharmaceutical result identify material topic diagnostic stand highly relevant key stakeholder significant economic develop manufacture deliver innovative environmental social impact material medicine diagnostic instrument test topic reflect business priority help million patient globally clear concrete action relate sustainable healthcare employee engagement environmental responsibility set priority aim achieve sustainable operational activity growth strategy emerge talent retention compliance growth deliver value stakeholder develop market compensationbenefits occupational accident pricing leadership commitment community engagement detail access healthcare chapter organisational effectiveness supply chain management executive compensation detail responsible business detail people chapter environment community chapter remuneration report information materiality process outcome wwwrochecommateriality roche highlight highlight roche hig hlig partnership foundation medicine fda breakthrough therapy designation fda breakthrough therapy designation carbon disclosure project recognition molecular information venetoclax form leukemia emicizumab ace hemophilia climate change mitigation approval lucentis fda breakthrough therapy designation positive phase iii result ocrelizumab fda approval cobas hbv cobas hcv approval alecensa diabetic retinopathy actemra systemic sclerosis form multiple sclerosis cobas hiv viral load test type lung cancer december january approval avastin positive phase result atezolizumab approval perjeta regimen launch roche national hpv primary approval cotellic plus advanced cervical cancer advanced bladder cancer early breast cancer pcr liquid biopsy test screen tender europe zelboraf advance melanoma fda breakthrough therapy designation fda clearance cobas flu test dow jones sustainability indices leader positive phase iii result gazyvagazyvaro atezolizumab type lung cancer use cobas liatsystem healthcare year running type nonhodgkin lymphoma leukemia roche chairman shareholder letter chairman shareholder letter roche remain sustainably successful successful research development new test medicine improve access medical solution key sustainable development business dear shareholder continue contribute achieve goal main contribution develop test sale grow strongly division medicine meet urgent pharmaceutical diagnostic enable medical need post net income chf billion despite substantial appreciation swiss franc owe area diagnostic particular primarily dedication passion likely play significant role future employee thank enable health manage effectively prevention target therapy unfortunately stand memory monitor chronic disordersand year war terror epidemic lot untapped potential event affect personally employee colleague friend harm strategic focus longterm success know crisis region conduct research field successful year father child ask probability success particularly high continue justice future generation medical need great want drive past year global economy double size progress medical option available patient global ecological footprint neurological disease endeavour time great environment recently produce strong result trial roche bear long term investigate treatment multiple sclerosis background encourage furthermore encourage opportunity new sustainable development goal adopt open information technology aim member states united nations september turn wealth medical datum valuable goal good health knowledge aid research selection christoph franz global healthcare company roche therapie individual patient chairman board roche chairmans shareholder letter chairman shareholder letter roche light strong performance delight finalised partner result improve insight specific regional light strong performance positive ship agreement foundation medicine national challenge local level tailor outlook board director propose propose dividend flatiron health field oncology plan address dividend increase chf share non relationship lead improvement vote equity security subject approval increase outcome cancer patient aware world poor country dividend increase year patent present hurdle provision important therapy reach basic medical care register addition reelection exist member patient need country enforce patent right country agm change board company found nearly year ago late medicine diagnostic freely affluent country patent create director aware dame deanne roche question status quo set available basic thing incentive need highrisk investment julius member board director new standard lacking example hivaid patent expire society benefit professor beatrice weder mauro board distribute medicine cost price important medicine permanently available member decide stand great pleasure insufficient healthcare worker facility reduce cost proud medicine reelection extraordinarily innovative company assure diagnostic tool administer therapy correctly develop feature world health valuable contribution year continue power ensure work overcome hurdle organisation essential medicine list company successful development behalf company continue deliver scientific partnership public private stakeholder lifesave antibiotic malaria cancer medicine roche board director like extend excellence benefit patient future like mention hiv global sincere thank access programme launch innovative healthcare company regard like thank shareholder partner unaid joint united nations sustainability responsibility growth delight able propose julie brown confidence company programme hivaid clinton health driver recent recognition demonstrate claudia sssmuth dyckerhoff new access initiative aim programme effort successful roche healthcare member board director provide certain lowincome country long company award maximum score wealth international management experience term supply hiv viral load test nonprofit organisation cdp chief financial officer british medical carbon disclosure project lead rank technology company smith nephew julie brown question access new product inevitably company response climate change extensive knowledge sale finance ethical component issue seriously seventh time row roche identify healthcare industry claudia sssmuth dyckerhoff want help patient gain access product sustainable healthcare company currently senior partner consulting firm include country low purchasing power dow jones sustainability indices mckinsey company leader christoph franz roche company establish healthcare system service practice asia chairman board differentiate pricing policy develop region award mean satisfied advanced access planning strategy status quo renew effort day stay ahead game live strong commitment sustainable name company apply sustainable healthcare company lady gentleman look forward welcome annual general meeting agm world year roche holding ltd march like opportunity mention important item agenda roche board director board director roche board director leave right bernard poussot paul bulcke peter voser prof beatrice weder mauro severin schwan dame deanne julius christoph franz chairman andr hoffmann vicechairman representative shareholder group pool voting right andreas oeri representative shareholder group pool voting right prof sir john irving bell prof richard lifton prof pius baschera corporate governance sustainability committee audit committee remuneration committee presidiumnomination committee nonexecutive director executive director committee chairperson roche board director december roche ceo shareholder letter ceo shareholder letter roche great year pipeline successful year great stride innovate medicine patient difficulttotreat disease include multiple sclerosis different type cancer hemophilia dear shareholder scientific success possible solid financial foundation year contain highlight strengthen sale increase particularly stand question group core earning share phase iii result present higher previous year positive investigational medicine ocrelizumab multiple result attribute continue strength sclerosis devastating disease current underlie business treatment vary benefit patient need well option potential improve pharmaceutical division oncology situation particularly primary progressive immunology contribute significantly sale growth diversity drive form chronic disease effective follow acquisition intermune treatment available particularly pleased report esbriet treatment fatal condition idiopathic oncology significant advance pulmonary fibrosisis show good growth cancer immunotherapy portfolio obtain positive highlight approval cotellic innovation outcomes bladder lung cancer pivotal trial combination zelboraf treatment lead candidate atezolizumab advance melanoma europe encourage improve sustain outcome see cancer patient invest diagnostic division launch new cobas strongly promise treatment approach instrument mark achievement milestone study investigational cancer automate integrate laboratory diagnostic severin schwan immunotherapy medicine new system permit substantially high test chief executive officer clinical trial throughput great flexibility provide growth rate report constant exchange rate average increase exclude onetime benefit chf million tax relate divestment filgrastim right roche ceo shareholder letter ceo shareholder letter roche innovationdriven company important benefit healthcare provider receive approval fda improve health outcome require stakeholder constantly strive efficiency gain laboratory alecensa alectinib treatment specific public privateto work closely employee play central role business contribute substantially diagnostic form lung cancer medicine create achieve sustainable solution convince division sale growth chugai approve japan roche succeed improve quality success simultaneously develop companion diagnostic healthcare globally continue incentivise roche facilitate improve laboratory test identify patient benefit true medical innovation work tissue sample stain central alecensa study correct diagnosis cancer roche employee current year expect sale grow low automation excellent stain quality lung cancer example disease commit medical innovation truly midsingle digit constant exchange rate core newly launch ventana system enable well understand molecular process make difference patient innovation earning share target grow ahead pathologist work great safety cancer cell shed light possible different drive company employee play central role sale constant exchange rate expect accuracy efficiency cause analysis molecular information success encourage diversity essential increase dividend swiss franc yield insight important foster new way think challenge continue good progress research development purpose status quo find new solution remain confident roche longterm product pipeline major approval target treatment patient roche innovation future science medicine progress fda breakthrough therapy designation mean simplify diagnostic patient talent management strategy focus give unprecedented rate thank new data medicine testament high level investing research bloodbase cancer test employee opportunity develop professionally analysis technique available continue innovation achieve research know liquid biopsy develop personally gain experience different role strong position develop new medicine development activity genentech cobas egfr mutation test roche help country global company increase diagnostic test well patient care chugai external alliance reflect broad minimise need intensive stressful surgical activity emerge market diversity people range approach idea example procedure collect tumour tissue sample experience increasingly valuable early development phase result emicizumab acea medicine develop chugai meaningful use large amount datum like thank employee prophylactic treatment people year old test result clinical practice set personal contribution shareholders hemophilia awhich sufficiently promise important role involve continued confidence roche start pivotal phase iii programme pilot project partnership severin schwan foundation medicine flatiron health chief executive officer highquality healthcare datum advanced analytic improve health outcome require improve development medicine scientific basis treatment decision stakeholderspublic privateto able realise plan work closely achieve continue develop business sustainably important strategy improve patient sustainable solution access innovative test medicine roche corporate executive committee corporate executive committee roche corporate executive committee leave right michael varney head genentech research early development gre roland diggelmann coo division roche diagnostic stephan feldhaus head group communication silvia ayyoubi head group human resources alan hippe chief financial officer severin schwan ceo roche group sophie kornowskibonnet head roche partnering prof john reed head roche pharma research early development pre osamu nagayama chairman ceo chugai gottlieb keller general counsel daniel oday coo division roche pharmaceutical roche corporate executive committee december member enlarge corporate executive committee roche business review business review roche sine thank strong business performance able enhance innovation capability deliver chf healthcare solution difference patient live billion group sale roche business review business review roche roche report strong result strong sale profit growth pharmaceutical growth drive increase demand oncology immunology group sale increase drive demand medicine primarily pharmaceutical sale strong uptake esbriet growth international strong demand immunodiagnostic product region drive key market include profitability growth ahead sale diagnostic roche extend industry brazil china japan sale grow exclude onetime income chf million lead product portfolio seven test pharmaceutical division sale rise drive avastin franchise sale filgrastim right core instrument launch chf billion increase drive new lung cancer medicine alecensa operating profit increase constant exchange oncology portfolio lead medicine rate basis core earning share strategic partnership improve patient care avastin sale immunology franchise grow diagnostic sale grow chf billion chf high january roche announce partnership drive strong uptake esbriet new asiapacific europe middle east flatiron health industry leader real medicine idiopathic pulmonary fibrosis africa emea main contributor ifrs net income increase constant exchange world oncology datum building collaboration high sale actemraroactemra xolair sale sale latin america north rate decline swiss franc term foundation medicine begin pegasy decline competition new america whilst sales japan stable major negative currency impact agreement important milestone drive generation treatment whilst valcytecymevene major growth driver professional diagnostic leadership personalise healthcare high xeloda face generic competition expect grow sale molecular diagnostic board director recommend dividend quality healthcare datum advanced analytic tissue diagnostic increase increase chf share nonvoting equity improve development medicine region contribute sale growth respectively diabetes care sale decrease security subject approval annual general quality treatment decision roche particularly strong performance continue challenge market condition meet shareholder march acquire ariosa diagnostic signature diagnostic europe drive strong especially roche consecutive annual dividend increase capp medical kapa biosystem company strong expertise technology product approval portfolio progress complement roche activity aim build key figure significant progress nextgeneration sequence portfolio product pipeline investigational medicine chf millions chf million change change cer chf ocrelizumab roche announce strong datum outlook group sale relapse primary progressive form multiple roche expect sale grow low midsingle pharmaceutical division sclerosis addition present promise result digit constant exchange rate core earning diagnostic division lead investigational cancer immunotherapy share target grow ahead sale constant core operating profit medicine atezolizumab bladder lung cancer exchange rate roche expect increase exclude filgrastim roche receive approval cotellic dividend swiss franc core ep diluted chf plus zelboraf treat metastatic melanoma exclude filgrastim approval cancer medicine alecensa ifrs net income specific form lung cancer growth rate report constant exchange rate cer average asiapacific eemea eastern europe middle east africa latin america canada exclude onetime benefit chf million tax relate divestment filgrastim right ifrs international financial reporting standard roche business review business review roche embrace dynamic market environment adjuvant therapy herceptin help prevent breast ultimate goal develop reliable test cancer patient develop metastasis base biomarker central personalise healthcare strategy focus innovation herceptin introduce adjuvant setting gamechange arena molecular information drive open door medical innovation roche recently enter strategic partnership focus genome sequence matter market evolve remain fully bactrim medicine treat analysis include foundation medicine commit central principle put bacterial infection medicine andme human longevity harness patient centre focus administer billion people worldwide genome sequence datum roche hope gain healthcare innovation work closely continue important impact number woman prevent develop metastasis deep insight disease biology enable external partner develop region incidence herpositive metastatic breast cancer identification new pathway biomarker herceptin target improve drug discovery primary contribution healthcare develop treat modern stateoftheart therapy develop well treatment improve patient care innovative medicine test improve hivaids chronic infection today patient major country prevent outlook patient year mortality rate drop roche develop metastasis effect adjuvant partnering critical strategy planning launch new medicine play important role develop herceptin give main treatment usually surgery healthcare industry vast majority come lab aim surpass standard innovative diagnostic test enable innovation happen outside single company care personalise treatment strategy breakthrough proud make progress outside truly innovative research likely flourish medicine like firstever protease inhibitor cancer difficulttotreat disease company strong inhouse capability market leader immunodiagnostic pcr multiple sclerosis currently limited diverse extensive network partnership tissue diagnostic increase offering leader oncology roche important treatment option debilitate disease sequence wellplaced deliver fully contribution significantly lower cancer mor announce strong latestage clinical study roche healthcare company integrate testing solution tality rate past year late result potential significantly recognise importance external innovation roche biopharmaceutical herceptin represent improve way treat currently run partnership last commitment improve life major step forward treatment particularly group consistently grow research aggressive form breast cancer year roche molecular information enhance decision groundbreake innovation past nearly bring cancer medicine prove past year roche optimise roche productivity year proud contribute survival benefit patient cooperation pharmaceutical major advance healthcare introduce diagnostic division translate scientific progress battle cancer new test target medicine show treatment especially difficult advanced impressive outcome example roche medicine include stage cancer metastasise remain study test investigational cancer medicine fully commit continue raise bar essential medicine list cancer patient outcome great potential process different cancer immunotherapy division share research facility technology combination treatment discovery work internal project roche industry early stage drug discovery biomarker roche success rate industry average provide critical information disease development base kmr general metric datum diagnostic involve early research project boston healthcare value innovation hivaid therapy roche business review business review roche emerge market account nearly expand access emerge market johannesburg provide handson certify committed working stakeholder inequality access healthcare increase training course facility boast selfcontaine find innovative pricing solution move away growth come year tremendous opportunity commitment laboratory late technological tool volumebase valuebase pilot programme overcome access barrier diagnostic test chemistry hematology molecular biology tissue show solution payer medicine world diagnostic sequence healthcare authority flexibility come reimbursement decision compliance requirement roche roche strongly believe critical new patient receive donate herceptin china basis license operate key uncover root cause country country able pap increase employee diversity implement mission improve patient live implement solution meaningful estimate nearly growth difference ground establish come emerge market come year seize right opportunity wide range policy programme partnership want sure people right experience risktake especially business prerequisite adapt need different local situation commit cultivate diverse talent innovation growth improve business performance pipeline help people company excel sustainable return key effectively manage establish patient assistance everchange business environment risk reduce negative uncertainty transform programme pap cancer foundation challenge business opportunity china patient group lead compliance integral culture significant increase access breast cancer approach science risk organisation place provide medicine herceptin pap implement business partner society commit structure support guidance proactively access medicine shortage high ethical social standard integrity assess risk opportunity catch equipment health education address number patient herceptin significantly increase fundamental business roche unaware unprepared inventory major group lack train diagnostic worker laboratory implementation roche pap china wide risk compile analysed annual capacity south africa run scientific campus transparency clinical trial information basis analysis publish group risk access barrier healthcare complex governance interaction key stakeholder report distribute review corporate multifaceted pricing major area group regular audits internal manufacturing executive committee board director patient access focus stakeholder majority process system legal help shape strategic decision market price medicine unitbase regulatory requirement herceptin roche patient undifferentiated drive volume therapy assistance programme china roche diagnostic diagnostic roche iag nostic market leader vitro diagnostic business provide large number test result empower physician patient informed health decision billion conduct roche instrument worldwide roche diagnostic diagnostic roche test provide critical information fast precise decisionmake medical care research development commercially available vitro diagnostic ivd well prediction therapy outcome test increasingly healthcare provider advance science drive rapidly grow screen diagnose monitor therapie test understand disease biology patient response critical lifesave emergency situation therapy new insight help answer critical immunodiagnostic test example help physi clinical question guide treatment decision cian onthespot treatment decision ensure effective safe therapy person stroke get well collect analyse molecular information thanks new technology virology increase demand deep gene sequence molecular information enable cervical cancer screen diagnostic test physician well predict outcome therapeutic noninvasive harmony prenatal test critically intervention optimise treatment strategy important pregnant woman provide accurate information risk baby understand lung cancer root driver mother increase number great example demonstrate benefit people diabete blood glucose meter molecular information dozen different lancing device insulin delivery system mutation cause disease potentially require important tool manage condition effectively different therapeutic intervention describe merely cancer specific organ describe molecular level scientific information help physician pinpoint mutation cause lung cancer physician well treatment decision well treatment decision ultimately improve outcome patient ultimately result well outcome patient roche diagnostic diagnostic roche diagnostic deliver strong growth meet different market requirement increase diagnostic annual sale contribute overall performance diagnostic sale increase continued good growth region roche group chf billion asiapacific europe especially asiapacific sustain strong middle east africa emea main sale increase china contributor growth sale china latin america record sale growth sale increase molecular diagnostic drive sale north america increase japan growth underlie molecular business sale stable sequence business major contribution sale growth come virology hpv tissue diagnostic increase sale drive market diabete business challenge growth professional diagnostic drive screening sale grow strongly emea growth advance staining portfolio diabete care sale decline immunodiagnostic clinical chemistry japan decline sale result nonrenewal include immunohistochemistry reagent continue challenge market condition coagulation monitor business tender blood screen large growth contribution come north blood glucose monitoring portfolio especially america emea sale blood glucose meter accuchek mobile grow sales accuchek performa major tender secure remain stable accuchek aviva decline sale netherlands roche award fiveyear lance device increase growth partially sale selling product chf millions contract national institute public health compensate impact phase old environment implementation product insulin delivery system business grow cobas hpv test firstline primary screening test drive infusion system newly national cervical cancer screening programme launch accuchek insight nextgeneration insulin delivery system combine insulin pump additionally major blood screen tender blood glucose meter contract thailand germany united kingdom spain significant competitive tender sale increase region latin america virology united kingdom france germany asiapacific decrease north america emea test run nextgeneration japan overall business efficiency gain accuchek aviva cobas cobas system implementation specific measure initiate cobas connect cobas ventana cobas streamline process reduce cost immunodiagnostic diabetes care clinical chemistry tissue diagnostic virology growth rate report constant exchange rate average roche diagnostic diagnostic roche transform laboratory practice automation connectivity highquality hardware interaction allow well quality control sample preparation ultimately lead reliable result medical health testing go dramatic doubling marketleade throughput paradigm shift hand new testing tech current instrument result nologie support large centralised laboratory hour key feature cobas new fully automate connect workflow conduct slide provide medically relevant result constant instrument laboratory analysis launch elecsys htlviii immunoassay laboratory country stain increase efficiency hand pointof hbac level blood sample people complete blood screen portfolio serology ventana system review care testing gain importance ensure diabete cobas essential tool provide unique ability combine pre pathologist excellent result immediate precise decisionmake spot healthcare provider cope everincrease analytic nucleic acid test serology testing offer increase testing capacity high level number people condition automate blood screen cobas rapid advance science result automation connect workflow cobas system connect workflow need molecular information laboratorie laboratory information system instrument key milestone fda approve make combination kind increasingly utilise number technology launch support customer cobas cobas system cobas market product receive market parallel include immunodiagnostic clinical transforming business hbv cobas hcv cobas hiv viral load test chemistry tissue analysis pcrbase technology fully automate system offer fast time launch ventana system gene sequence marketleading example cobas automate workflow result high throughput long walk globally fully automate hematoxylin eosin portfolio immunodiagnostics pcr tissue series fullyautomate system cover away time available automate molecular tissue stain system enhance patient analysis progress sequence operational preanalytical integrate post platform provide laboratory improve safety avoid crosscontamination produce year forefront analytical step laboratory sample operating efficiency flexibility adapt exceptional stain quality support laboratory business transport technology enable connectivity change testing need analytical archiving device design system improve workflow eliminate highthroughput laboratory capacity new test generation viral load need manually mix reagent global test sample hour test clinician use manage treatment people hepatitis hepatitis virus hiv approval follow launch diabete new cobas double system test country accept mark throughput result hour wwwrochecomproduct conformit europenne symbol free marketability european economic area roche diagnostic diagnostic roche modern target therapy diseasecause mutation unknown egfr meet splice site alk fusion meet amplification kra braf broaden portfolio nra pikca ros fusion akt kifbret mapk multiple test connect system test approval launch accuchek connect fully integrate diagnostic multiple genetic mutation cause nonsmall cell lung cancer past variation distinguished today molecular information support year broaden industryleade product system app online portal fda treatment decision effective target therapy portfolio new elecsys htlviii immunoassay approve bolus calculator improve diabete self diagnostic test help detect antibody management launch human tlymphotropic virus infection donate blood routine diagnostic sample fda grant clinical laboratory improvement amendment clia waiver assist clinician make timely treatment september launch cobas egfr design need blood centre clinical cobas strep test use cobas liat system decision aids prevention mutation test oncology test utilise laboratory reliable efficient detection streptococcus responsible wide range infection healthcare setting plasma tumour tissue sample test microorganism test enhance blood invasive noninvasive infection identify mutation epidermal growth screen portfolio serology testing build cliawaive pcr test detect strep cobas hsv herpe simplex virus factor receptor egfr gene vitro current offering comprehensive throat swab specimen test direct detection differentiation diagnostic market test blood screen hsv hsv dna symptomatic patient aid select eligible patient nonsmall cobas influenza test use cobas liat receive fda clearance dualtarget cell lung cancer nsclc therapy egfr improve cardiac pointofcare troponin test system receive clia waiver easytouse detection automation test provide tyrosine kinase inhibitor cobas system available country test nontraditional testing site laboratorie capability report accept mark allow healthcare professional physician office emergency room result significantly time traditional target therapy available rapidly identify patient suspect acute healthcare facility provide result point method provide simplified workflow critical provide oncologist innovative myocardial infarction term heart attack care sample handle laboratory molecular testing method easy great accuracy low troponin concentration patient test subject surgery handheld pointofcare diagnostic system cobas hiv hbv hcv hcv genotype risk tumour tissue availability place heart attack patient assay launch country accept see ambulance emergency room mark new molecular diagnostic assay primary caregeneral practitioner office increase available menu cobas system improve efficiency flexibility allow laboratory deliver result rapid new cancer test allow clinical decision detection cancer blood fda provide clearance cobas cdiff test detect clostridium difficile difficile stool patient sick invasive specimen test provide accurate information tissue biopsy davenport egfr testing lung cancer patient medscape medical news roche diagnostic diagnostic roche personal perspective liquid scientist honestly dream job biopsy test addition complement tissue biopsy ability detect trace detect cancer liquid biopsy enormous broad diagnostic potential colleague lin hypothesise use technology monitor patient response treatment cancer surgery development drug resistance clinical result confirm hypothesis thrill team potential personalise cancer therapy walter koch phd head research hiv hepatitis patient occasion calibre scientific research roche molecular diagnostic conduct colleague make proud build cobas egfr mutation test new era cancer expand application technology accuracy egfr activate colorectal breast type cancer resistance mutation present nonsmall cell diagnostic lung cancer patient explore liquid biopsy actionable gene fusion small genetic sequence liquid biopsy test run cobas microribonucleic acidsopene exciting new interested cancer start diagnostic platform find community horizon term detect treat working lab technician age today hospital mean fast result mean monitor cancer head research roche molecular diagnostic great access target therapy patient comprise talented people scientist test egfr mutation honestly dream job develop country lack tissue test long opportunity work lab test positive liquid biopsy patient team push new frontier start target therapy roche tarceva science insight translate fact tarceva team suggest diagnostic help well detect cancer support development liquid biopsy test disease illustrate synergy pharmaceutical diagnostic roof roche good example cobas egfr mutation test detect dna nonsmall cell lung cancer liquid biopsy technology offer benefit plasmathe yellowish liquid remain patient current practice detect cancer blood cell remove blood base microscopic examination tumour tissue hour little plasma detect acquire surgery invasive biopsy patient sense excitement learn new simply sick undergo procedure day share success team roche pharmaceutical pharmaceutical roche phar mace utical roche provide medicine truly improve patient live recently approve combination therapy cotellic plus zelboraf advanced melanoma roche bring option patient lifethreatene hardtotreat disease million patie treat roche sell medicine roche pharmaceutical pharmaceutical roche focus disease area high unmet medical need expertise real difference patient world leader oncology medicine nonsmall cell lung cancer nsclc datum helped revolutionise treatment type present american society clinical cancer avastin example design target oncology demonstrate importance angiogenesisa process new blood vessel understand immune biology cancer treatment form help tumour growavastin present new pivotal datum gazyva pillar cancer treatment today avastin gazyvaro show medicine approve treat seven different type cancer improve outcome patient difficult totreat indolent nonhodgkin lymphoma inhl medicine target herpositive breast cancer herceptin perjeta kadcyla allow people receive marketing approval new target advanced disease live long therapy include cotellic combination earlystage cancer chance sustain remission zelboraf advanced melanoma alecensa mabtherarituxan monoclonal antibody specific type lung cancer believe future remain widely medicine treat cancer treatment lie combination therapie common form blood cancer avastin target treatment cancer immunotherapy herceptin mabtherarituxan play role treatment seven million patient oncology esbriet new medicine treat idiopathic gain important insight pulmonary fibrosis fatal lung disease wave cancer therapy recognition make big difference patient year pipeline innovation exciting datum key approval market present datum suggest fda grant second breakthrough therapy continue treatment esbriet early designation lead cancer immunotherapy hospitalisation help slow disease progression candidate atezolizumab time pdl positive announce important new data treatment multiple sclerosis positive jeffrey schwartz picture right latestage clinical study investigational medicine ocrelizumab confirm hypothesis participate cancer cell central pathogenesis disease submit datum regulatory authority immunotherapy clinical trial marketing approval roche pharmaceutical pharmaceutical roche pharmaceutical deliver strong growth drive oncology immunology increase pharmaceutical annual sale drive roche group overall pharmaceutical sale increase japan kadcyla sale drive primarily performance chf billion key driver include herceptin demand europe perjeta kadcyla combine positive breast cancer herpositive metastatic mabtherarituxan common form blood gastric cancer herceptin herceptin sale cancer include nhl follicular lymphoma grow strongly especially long chronic lymphocytic leukemia rheumatoid duration treatment combination perjeta arthritis certain type vasculitis perform avastin advance colorectal breast lung actemraroactemra rheumatoid early advanced breast cancer strong demand sale growth drive primarily strong demand kidney cervical ovarian cancer glioblastoma arthritis systemic juvenile idiopathic arthritis see international region notably demand continue increase type brain tumour post strong sale growth polyarticular juvenile idiopathic arthritis record china brazil perjeta see strong oncology immunology sale increase increase sale see region strong growth sale increase region drive growth particularly europe international region lead increase demand rise demand ovarian colorectal lung cervical strong demand subcutaneous formulation approve use surgery earlystage brazil china japan cancer follow launches europe emerge particularly europe aggressive breast cancer good growth market strong growth see june fda grant breakthrough therapy international region particularly designation actemra systemic sclerosis china uptake colorectal cancer key growthdriving product chf million new lung cancer indication fuel growth japan esbriet chf million idiopathic pulmonary growth drive demand breast fibrosis ipf fatal lung disease continue lung cancer strong uptake approve fda swissmedic sale reach chf million lucentis eye condition wet age chf million europe chf million relate macular degeneration wamd macular edema international region september additional follow retinal vein occlusion rvo diabetic datum present pool analysis macular edema dme impact competitive phase iii study suggest reduction pressure wamd dme segment treatmentemergent risk death ipf patient february fda approve lucentis take esbriet year additional indication diabetic retinopathy people avastin herceptin perjeta kadcyla esbriet dme oncology oncology oncology oncology immunology growth rate report constant exchange rate average asiapacific eemea eastern europe middle east africa latin america canada nathan effect pirfenidone treatmentemergent allcause mortality acm patient idiopathic pulmonary fibrosis ipf pool datum analysis ascend capacity roche pharmaceutical pharmaceutical roche significant breakthrough advance patient care fda grant breakthrough therapy fda grant priority review venetoclax major regulatory milestone designation medicine designation investigational medicine develop help accelerate development review partnership abbvie patient hard product project description medicine intend treat disease totreat type chronic leukemia follow fda breakthrough atezolizumab pdl positive nsclc demonstrate substantial improvement exist second breakthrough therapy designation therapy designation emicizumab ace hemophilia factor viii inhibitor therapie total receive designation venetoclax combination mabtherarituxan actemraroactemra systemic sclerosis time testament commitment relapse refractory cll aml venetoclax deletion relapsedrefractory chronic lymphocytic leukemia innovation acute myeloid leukemia aml target cancer therapy approval mabtherarituxan relapse refractory cll breakthrough therapy designation fda european commission filing avastin tarceva egfr mutationpositive nsclc submit datum fda lead investigational approve cotellic combination zelboraf avastin advanced cervical cancer japan cancer immunotherapy medicine atezolizumab treatment people braf mutation gazyvagazyvaro rituximabrefractory indolent nonhodgkin lymphoma treatment people metastatic bladder cancer positive metastatic melanoma update pivotal datum approval alecensa secondline alkpositive nsclc plan submit datum fda show combination help people live avastin advanced cervical cancer breakthrough therapy designation atezolizumab significantly long median year lucentis diabetic retinopathy diabetic macular edema treatment people nsclc express compare zelboraf perjeta early herpositive breast cancer neoadjuvant presurgical treatment pdl disease worsen cotellic zelboraf brafpositive metastatic melanoma standard treatment submit plan fda approve alecensa people submit datum cancer type global health advance alkpositive nsclc disease authority present promise datum progress follow treatment crizotinib atezolizumab specific type advance breast second approval medicine year fda grant cancer melanoma medical conference create chugai member roche group approve japan submit breakthrough therapy designation american society hematology present marketing authorisation application ema followup result pivotal study people indication roche medicine inhl relapse month target therapy approve treatment mabtherarituxanbase companion diagnostic building leadership regimen subgroup analysis people personalise healthcare patient respond follicular lymphoma common type inhl medicine way diagnostic treatment gazyvagazyvaro plus bendamustine test possible well understand disease provide significantly great depth remission patient respond treatment sale end induction compare bendamustine product companion test label represent fda grant breakthrough therapy designation venetoclax combination mabtherarituxan treatment people relapse pivotal study datum submit approval pharmaceutical division sale refractory chronic lymphocytic leukemia cll january venetoclax acute myeloid leukemia aml january roche pharmaceutical pharmaceutical roche approximately people approximately people north america europe promising result multiple sclerosis potential new treatment option disease central nervous system multiple confirm central role cell sclerosis chronic disease decade scientist pioneer immune system abnormally attack insulation concept selectively target component prevalence high country furth approximately people support nerve cell brain immune system cdpositive cell spinal cord optic nerve cause inflammation effective therapeutic approach people equator australia damage people diagnose disease prime life whilst concept widely accept year age affect approximately million medical community scientist conduct mapping incidence world people worldwide indepth research follow development programme longterm view commitment patient relapse disease common development ocrelizumab humanise form attack period time symptom monoclonal antibody target specifically flare primary progressive form cdexpresse cell hypothesis cell progression clinical disability compare medicine base broad expertise affect patient suffer disability central pathogenesis relapse placebo safety profile similar placebo develop number innovative medicine continuously worsen onset confirm neuroscience disease typically distinct relapse ocrelizumab investigational medicine period remission compelling study result positive study result primary progressive strong pipeline industry datum phase iii study opera relapse form affect approximately develop medicine range cure treatment opera demonstrate clinically meaningful people time diagnosis neurological disease include approach vary degree benefit benefit ocrelizumab people relapse submit ocrelizumab datum global regulatory alzheimer disease autism spinal muscular atrophy patient present result pivotal study ocrelizumab compare authority form early depression parkinson disease syndrome phase iii clinical study investigational approve standardofcare interferon detail medicine ocrelizumab provide hope show treatment ocrelizumab lead result build deep understanding new paradigm treatment significant reduction frequency immunology develop novel antibodybase relapse progression clinical disability loss physical ability number lesion lead cause nontraumatic brain safety profile similar standard care disability young people usually phase iii study oratorio assess rebif register trademark merck kgaa emd serono inc multiple sclerosis international federation atlas strike year age ocrelizumab primary progressive debilitate national institute neurological disorder stroke multiple sclerosis hope research simpson latitude form disease demonstrate reduction significantly associate prevalence multiple sclerosis metaanalysis neurol neurosurg psychiatry roche pharmaceutical pharmaceutical roche personal perspective teamwork perseverance enable succeed convinced whilst team move ahead right thing ocrelizumab form tightknit subteam develop comparator placebo break active comparator component part design comparator placebo leverage external patient manufacture network produce placebo syrinx meet strict requirement human injection drug face obstacle merciless tick rita wong head global biologics clock teamwork perseverance enable succeed produce comparator manufacturing science technology drug product placebo time convince right thing patient set high bar test ocrelizumab allow produce compelling doubleblind comparative clinical datum context roche clinician want increase scientific characterised active comparator rigour phase iii trial compare design ocrelizumab standardofcare medicine take current position keep approve treatment arm eye clinical trial october positive doubleblinde meaning patient phase iii result ocrelizumab release intensely curious person clinician know receive placebo hard work worth favourite word natural investigational medicine scientist inquisitiveness helped decade work ocrelizumab technical development team supply investigational medicine study patient material clinical trial study multiple sclerosis msa disease strike arm scale production ocrelizumab young adult prime life produce placebo formulation identical appearance administration intravenous infusion join genentech right college hire formulation development group second arm purchase drug simply state ensure active ingredient standardofcare medicine approve treatment medicine remain stable usable begin work develop placebo look ocrelizumab formulation year like market comparator drug come later appoint technical development leader syringe multiple dose different presentation prior phase iii trial roche clinical trial design allow clear benefit month start trial patient roche innovation innovation roche innovation broad portfolio new molecule address high unmet medical need forefront transform science new therapy new molecular entity clinical development roche innovation innovation roche lmost decade ago transform activity interconnect pharmaceutical diagnostic research increase investment external innovation approach foster scientific diversity position develop nextgeneration test creativity need develop powerful test medicine medicine deliver today industry research early development carry tomorrow mean year value early organisation genentech research early entry personalise healthcare see development gre roche pharma research broad deep pipeline include grow early development pre chugai pharmaceutical number target drug candidate companion ltd japan member roche group diagnostic today see new treatment diagnostic division winwin approach combine therapy attack partnership alliance external illness different angle hold great promise company institute turn cancer complex disease chronic condition people live trigger explosion scientific insight molecular genetic data expert forefront current biological revolution additional discipline collaborate closely researcher think disease today roche master challenge complex immune system fundamental molecular disease pose development team compound cellular level look harness successfully develop gre pre chugai vast increase molecular information partner progress global latestage important step effort develop well development organisation personalise treatment solution core investment roche group pharmaceutical diagnostic chf chf chf sale sale sale growth rate report constant exchange rate average roche innovation innovation roche transforming care new treatment new era tackle cancer cancerimmunity cycle learn tumour year develop disrupt cycle disable hiding medicine improve redefine coopte immune response point science well patient care oncology treatment believe advance cancer way goal cancer immunotherapy therapy progress dramatically research identify understand counteract emerge field cancer immunotherapy base tumour ability suppress immune response understand biology cancer immune system molecular level cancer scientist focus inhibit diverse know diagnosis people therapy decade recently immunotherapy aim provide patient mechanism tumour use sabotage stem completely different genetic cause invest heavily emerge field tailor treatment power immune system stimulate immune meaningfully disease fact cancer immunotherapy inroad immune system fight particular cancer response cancer programme single disease worldclass scientist understand multifaceted biology include cancer immunotherapy roche group uncover intricate detail immune response individual cancer view today investing bring candidate target step cancer disease biology root molecular cause biological diversity adaptability cancer personalise cancer immunotherapy physicians immunity cycle example overexpression cancer inflammation neurological disorder believe combination therapy design accord grow toolkit target medicine protein program death ligand pdl cancer rheumatoid arthritis complex disease specificity disease presentation play cancer diagnostic test immune cell block stage time dive deep human important role battle cancer accurately predict likely respond cancerimmunity cycle inhibit pdl biology unlock mystery immune atezolizumab thwart disruption allow systemhow fight surrender overwhelm gamechange arena molecular information harness immune system fight cancer immune cell attack tumour interact enemy cellular battlefield drive require update area cancer cell use cellular camouflage avoid product development basic research target attack immune system long time new drug candidate offer promise diverse insight drive groundbreaking identification molecule design clinical research unclear cancer cell go undetected atezolizumab investigational antibody design discovery transform medicine identification relevant biomarker development scientist include expert roche fight tumour block pdl protein practice instance pioneer companion test addition recast group unravel mystery cancer pdl produce surface tumour concept confirm hypothesis longstanding model clinical study bring evade immune system start grow immune cell believe act stop sign cell central pathogenesis multiple effective treatment patient fast spread knowledge develop block immune cell recognise attack sclerosis announce exciting result learn standardise validate cull good medicine harness bodys immune system destroy cancer cell dozen latestage clinical study submit use astounding volume scientific realworld fight cancer different tumour type hijack pdl datum regulatory authority approval datum generate day increasingly interaction atezolizumab remove cellular critical decision roche regulator payer datum number roche clinical study camouflage tumour allow immune proud legacy paradigmshifting ultimately provider patient present month reveal cancer cell attack cancer innovation include treatment disease immunotherapy extraordinary promise central nervous system powerful anti whilst main focus oncology inflammation treatment previously fail treat bladder cancer phase imvigor study infective cancer immunology neuroscience infectious disease advanced cancer immunotherapy show atezolizumab shrank tumour ophthalmology open area patient terminal cancer live people metastatic urothelial carcinoma muc real difference patient extensively long period time compare benefit disease medium high level pdl diving deep human biology help progress treatment classical treatment expression worsen initial treatment disease year ago viable result assess people understand immune system treatment option tremendous unmet target cancerimmunity cycle respond atezolizumab continue respond medical need remain immune system protect body cancer engage cancer understand multistep roche innovation innovation roche release cancer cell antigen cancer antigen presentation kill cancer cell prime activation cancer phase study evaluate atezolizumab people believe diagnostic information immunity advanced nonsmall cell lung cancer nsclc important physician patient cycle randomise phase study poplar show opportunity incorporate available information people recurrent nsclc tumour treatment decision differentiate express medium high level pdl survive patient likely benefit monotherapy statistically significant month long consider migration cell tumour people receive docetaxel chemotherapy alternative treatment strategiesfor example recognition cancer cell cancer immunotherapy combination clinical trial separate pivotal singlearm phase study birch important consideration making show drug candidate shrank tumour treatment decision people disease progress infiltration cell tumour prior medicine express high way target cancerimmunity cycle level pdl think tumour able evade recognition immune system atezolizumab study median counter tumour ability hide immune cancerimmunity cycle survival reach adverse system develop specific diagnostic illustration immune system recognise kill cancer cell patient cycle fail number point event consistent observe understand type tumour good deliver adapt chen mellman previous study appropriate treatment strategy step cancerimmunity cycle fda grant breakthrough therapy scientist look difference designation atezolizumab treatment expression pattern immunoregulatory molecule muc nsclc respectively people respond treatment versus ultimate goal bring benefit promise production immunosuppressive metabolite ido aim identify patient cancer immunotherapy people block proliferation effector cell whilst companion diagnostic guide therapy decision benefit specific combination therapy great need new treatment option promote generation regulatory cell keep personalise healthcare strategy monotherapy identify new target roche group scientist identify broad counteract fighting activity effector cell atezolizumab study include evaluation drug discovery pipeline compound target different cancer investigational immunohistochemistry test develop immunity checkpoint cycle furthermore ido express apc pro inhouse use specific antibody measure research indicate patient tumour tolerogenic unable prime effective immune pdl expression tumour cell inflame active invasion immune strategy employ tumour block response presentation cancer protein infiltrate immune cell cell high response rate atezolizumab cell activity ido protein induction ido antigen lymph node tumour patient noninflame tumour lack expression unregulate tumour cell andor microenvironment result ido expression invasion antigenpresente cell apc situ help tumour evade immune system ongoe plan depletion extracellular tryptophan block effective antitumour immune response work find new way deepen phase iii study atezolizumab treatment response atezolizumab inflame tumour turn noninflame tumour kind lung kidney inflame tumour combination therapie atezolizumab potentially trigger response breast bladder cancer chen mellman oncology meet immunology cancerimmunity cycle immunity roche innovation innovation roche atezolizumab foundation cancer immunotherapy portfolio multiple combination multiple combination activate additional antagonist signal immune cell divide proceed perform inhouse partner attack ilv design favour immunestimulatory research develop compound target immunesuppressive cell create tumour ido tdo tryptophandioxygenase hostile milieu specific target antibody chemotherapy protein like ido involve tryptophan expect act strongly tumour degradation firstinclass dual idotdo inhibitor host organ lead reduce cytokinemediate develop curadev pharma private toxicity see current therapy limit research agreement launch portfolio immunotherapy portfolio newlink genetic corporation discovery support immune system alecensa avastin cotellic gazyvagazyvaro acd acdcd tdb aceailv nextgeneration idotdo compound small order help immune system identify herceptin kadcyla mabtherarituxan aox acsfr humab afapilv molecule idoinhibitor rggdc engage tumour cell design unique perjeta tarceva zelboraf atezolizumab ceatcb idoi indolamine dioxygenase ido checkpoint form engineer cell bispecific antibody molecule clinic project pipeline clinical trial inhibitor develop collaboration redirect cell tumour cell newlink genetic currently clinical specific manner cell bispecific antibody development ido inhibitor incb bind simultaneously target tumour cell develop collaboration incyte include cea target cell separately begin investigate newly provoke cell activation cell proliferation example work type cancer suppress cell promote tumour discover immune receptor target know cell infiltration destruction tumour vaccine trigger tumourspecific cell growth formation cancerinduce blood tigit cell immunoreceptor itim bispecific antibody target cea find response patient response vessel combination study patient domain play role finetune surface colorectal gastric cancer occur spontaneously begin antiox antibody response pancreas lung breast cancer ido inhibitor phase clinical dive deep complex biology inhibit tumour ability sabotage development tumour immune system increasingly cancer immunotherapy immune system explore pathway believe combination treatment approach research development compound activate immune response apc test antibody moxr hold great promise cancer patient currently test clinical study multiple highly effective stimulator cell activate design stimulate immune response activate currently numerous study underway internally combination investigation comprehensive antibody engineer bind surface signal pathway tumour tissue partner test atezolizumab combination cancer immunotherapy programme cover total protein boost apc represent eliminate immunosuppressive regulatory cell immunomodulator trial underway lung kidney breast additional tactic augment number active lymph node soon apc transport lead tumourtargete therapy avastin cancer ultimately expect cancer immunotherapy effector cell agonist activate tumour antigen stimulate growth cell zelboraf spawn new era oncology development apc engulf tumour antigen battle tumour cell test phase therapy transform deadly cancer chronic stimulate tumour reactive cell clinical trial single agent combination phase clinical trial initiate combine disease patient live long time develop combination immuno atezolizumab drug candidate hold promise atezolizumab emactuzumab antibody therapeutic antibody include atezolizumab treat type cancer colonystimulating factor receptor new molecular entity involve production tumourassociate cytokine fusion protein strategy cancer vaccine immunotherapy combination macrophage tam emactuzumab block clinical study cancer immunotherapy mobilise cell tumour antibody researcher explore innovative approach activity survival tam prevent binds carcinoembryonicantigen cea enable immune response tumour protein find surface cancer specific effector cell find carry molecule call interleukin variant ilv tumour tissue immune environment roche innovation innovation roche personal perspective experience cancer help special empathise patient opportunity regain weight lose importantly able read play small child impacta year later start clinical study pleasure meeting jeff express interest meet doctor special experience know scientist physician datum point clinical study jeff story extremely gratify level continue today result like oncologist incredible sense fulfilment purpose dan chen phd cancer immunotherapy franchise head patient respond jeff therapy global product development oncology address particular pathway immune system know pdl opportunity cancer cell camouflage escape immune system immune response lead work help focus mind spirit understand immune system work year half miss day cancer rapidly develop new way fight cancer work treatment tough help immune system recognise fight cancer time location tumour able biopsy come grip new insight occur cancer immunotherapy scientist fascinate uncertainty go live die day amazing time field potential harnessing bodys immune job special opportunity impact system fight cancer particularly encourage today investigational cancer scientist physician progress make area roche immunotherapy see case unlike realise potential year medical practice patient clearly near end recall regain train medical oncologist see life continue patient fight bravely cancer desperate time doctor patient jeff schwartz counsellor friend watch diagnose stage sarcomatoid renal cell lose battle carcinoma february metastasis spread body tell kidney personal glimpse specialist month live difficult journey fight informed mri show december jeff start clinical trial twocentimetre tumour spine tumour cancer immunotherapy time crush nerve spine put pain start treatment barely bed pleasure meet jeff express interest meeting excruciate frightened child study jeff respond treatment doctor oncologist omid hamid roche innovation innovation roche positive pipeline news flow prostate cancer factor viii inhibitor trial pediatric ipatasertib akt inhibitor develop patient year old hemophilia partnership array biopharma reach efficacy inhibitor factor viii strong datum clinical study safety endpoint combine abiraterone phase trial patient castrationresistant neuroscience prostate cancer previously treat docetaxel number investigational medicine chemotherapy activation pikakt pathway clinical development neurological disorder associate poor prognosis lead include multiple sclerosis alzheimer disease gain great understanding tumour idasanutlin currently study phase iii resistance standardofcare therapie ipatasertib parkinson disease spinal muscular biology immune function cancer divide trial relapsedrefractory acute myeloid leukemia block signal akt combine atrophy sma syndrome autism spectrum specific subtype define aml idasanutlin firstinclass mdm antihormonal therapeutic like abiraterone disorder pain location body increasingly antagonistp activation investigational medicine potentially extend duration benefit ipatasertib molecular structure protein marker genetic inhibits tumour cell growth induce tumour study combination chemotherapy multiple sclerosis mutation signal pathway scientist cell death phase iib study idasanutlin show patient triple negative breast cancer positive result phase iii study verify root genetic cause find new way consistent durable complete remission aml opera opera ocrelizumab relapse conquer difficult treat lifethreatening disease hemophilia phase iii study oratorio primary high morbidity unmet medical need idasanutlin hemophilia rare genetic disorder occur progressive present relapse leukemia lymphoma show orr single agent orr essential bloodclotting protein call factor viii ocrelizumab significantly reduce annualise positive datum phase study combination chemotherapie arac present sufficient amount defective relapse rate primary endpoint study venetoclax investigational small molecule phase iib study fda grant breakthrough therapy nearly compare interferon medicine develop partnership abbvie designation emicizumab ace twoyear period primary progressive show clinically meaningful reduction patient aml need new therapy bispecific antibody treatment factor viii oratorio study meet primary endpoint show number cancer cell overall response rate orr increase survival inhibitor people severe hemophilia treatment ocrelizumab significantly reduce people previously treat relapse significant progress regard year old development inhibitor risk progression clinical disability sustain refractory chronic lymphocytic leukemia cll decade addition phase iii trial idasanutlin antibodie develop bodys immune system week compare placebo deletion firstinclass molecule study phase ibii trial combination attack destroy replace factor viii bind bclprotein help restore natural venetoclax aml combination complication hemophilia treatment alzheimer disease process cause cancer cell selfdestruct gazyvagazyvaro nonhodgkin lymphoma regardless disease severity make difficult research focus pathway believe study patient previously treat cll addition investigate bispecific impossible achieve level factor viii sufficient play important role disease include genetic mutation know deletion antibody target cdcd design control bleed traditional replacement amyloid tau clinical research finding present mutation see approximately bind target patient leukemia lymphoma therapy base encourage datum phase confirm hypothesis amyloid play cll patient typically poor result cell whilst time bind iii study show promise efficacy important role development progression exist therapy target cell redirect cell weekly subcutaneous administration emicizumab addition early research indicate tau attack cancer cell antibody different pivotal study start enrolment late implicate disease multiple pathway venetoclax study phase iii trial mechanism action rituximab currently trial evaluate emicizumab people potential pathology contribute develop cll phase study treat blood cancer preclinical testing hemophilia inhibitor factor viii ment progression disease research blood cancer abbvie submit nda suggest circumvent rituximab resistance year old prepare initiate portfolio position contribute significant fda breakthrough therapy designation additional trial include phase iii trial advance disease area continue generate ema submission regulatory authority emicizumab people hemophilia datum early late development stage world plan astermark overview inhibitor seminar hematology roche innovation innovation roche investigational compound latestage amyotrophic lateral sclerosis sma affect motor neuron muscle smnsplice modifier clinical testing development crenezumab monoclonal antibody conduct research amyotrophic activity crawl walk head neck clinical trial investigate safety tolerability design target form amyloid lateral sclerosis know lou gehrigs disease control swallow common pharmacokinetic pharmacodynamic move phase iii clinical development disorder involve death neuron rare disease bear sma healthy individual start january prodromaltomild monoclonal antibody especially motor neuron people progressive gantenerumab design decrease level neurodegenerative disease suffer stiff muscle olesoxime investigational medicine huntington disease aggregate amyloid recruitment muscle twitch gradually worsen weakness evaluate potential ability preserve rare genetic neurological disease cause stop phase iii study gantenerumab people muscle waste result difficulty healthy spinal motor nerve cell result peopleto experience deterioration mental mild dementia marguerite road speak swallow eventually breathe year phase iiiii clinical trial involve people ability motor control presently analysis datum phase iiiii scarlet road type nonambulatory type sma indicate diseasemodifye treatment study provide evidence people early neurodevelopmental disorder olesoxime stabilise neuromuscular function collaborate ionis pharmaceutical develop benefit high dose gantenerumab continue commitment find new treat reduce medical complication associate rnatargete medicine treatment participant scarlet road marguerite ment option people neurodevelopmental disease year compare placebo mid patient enter phase iiia road study offer treatment disorder include autism spectrum disorder olesoxime cholesterollike compound bind clinical study evaluate ionishttrx high dose gantenerumab assess tolerability syndrome phase trial underway protein find mitochondria cell source therapy enter clinical development design safety evaluation high dose datum test safety tolerability receptor cellular energy production powerhouse reduce production form huntingtin discussion health authority antagonist people autism spectrum cell olesoxime design reduce release htt protein include mutant huntingtin decide step clinical development disorder compound improve core cell death factor mitochondria promote protein responsible gantenerumab social communication interaction deficit survival spinal motor nerve cell olesoxime people disorder grant orphan medicinal product designation immunology inflammation parkinson disease treatment sma european medicine different type monoclonal antibody target syndrome ongoing phase agency orphan drug designation fda autoimmune disease chronic synuclein protein misfold study investigate adolescent adult debilitating lifethreatene involved pathogenesis development year age start collaboration ptc therapeutic currently available therapy unspecific generally collaboration prothena currently phase trial study investigational compound sma foundation develop smnsplice target immunosuppression address study phase trial involve people child year age preclinical data modifier treatment sma phase disease cause expand immunology inhouse develop smartphone app show selectively modulate gabaa moonfish trial investigate safety inflammation research early development continuously measure symptom fluctuation receptor brain possible stimulate people sma place clinical hold april effort recognition high unmet need people potentially time learn memory pathway lead improve decision suspend dose moonfish recent scientific advance lead well approach measure disease ment cognition function adaptive take roche precautionary measure stand molecular mechanism underlie symptom severity medicine development behaviour people syndrome observe unexpected finding animal study disease scientist focus pathway programme remote patient monitoring evaluate longterm safety continue underlie adaptive immunity innate immunity system work combination patient spinal muscular atrophy thoroughly assess safety finding ongoing tissue inflammation fibrosis input passive tracking app rare debilitate genetic neuromuscular animal study advance second backup ongoing trial continuous measurement disorder sma commonly diagnose daily symptom fluctuation ultimately child lead hereditary cause infant hope app future clinical mortality sma cause mutation deletion development enable objective measure smn gene characterise insufficient patient response treatment complement level smn protein lead progressive loss physicianle assessment motor neuron muscle weakness atrophy roche innovation innovation roche increase risk future severe exacerbation decline lung function severe asthma lead unacceptable daily symptom hospitalisation internal programme cathepsin diseasemodifye therapy lampalizumab cat inhibitor believe phase iii study currently ongoing reduce specific molecule available severe asthma impact quality life patient caregiver increase medical burden society antigen presentation limit immune additionally pioneer development response potentially apply highly innovative bispecific monoclonal antibody treatment multiple autoimmune disease cat target vegfa angiopoietin involve central pathway adaptive immunity ang angiogenic growth factor mean severe asthma current medication programme gdc novel spur blood vessel growth phase infectious disease bruton tyrosine kinase btk inhibitor help clinical study neovascular amd rise bacterial resistance threat break severe asthma cycle block cell proliferation result excessive bispecific antibody develop rocheinvente global health line strong legacy immune response see autoimmune disorder crossmab technology tightly bind vegfa antibiotic leverage significant knowhow gdc bind btk novel way arm ang arm randomise active address century problem early study believe increase effectiveness offer comparatorcontrolled phase study currently underway novel antibody target potential compound phase tlr promise patient difficulttotreat investigate safety efficacy cause reinfection staphylococcus aureus agonist compound phase autoimmune disease patient choroidal neovascularisation secondary leverage breakthrough cancer technology development lead amd leadingedge trojanhorse type platform partner inovio molecule hbv parallel discovery activity strive sneaks drug bacteria platform portfolio develop centre alliance area key academic respiratory disease potential resistant infection shanghai china recognition heavy burden biotech partner october acquire lebrikizumab target protein find people partnership meiji seika pharma fedora hbv put china sdp adheron therapeutic moderate severe uncontrolled asthma develop nextgeneration lactamase monoclonal antibody target cadherin phase iii development datum expect inhibitor advance candidate treat patient believe disrupt tissue cell interaction drive thorax publish phase iib study result hepatitis virus hcv infected inflammation nonimmunosuppressive manner show lebrikizumabtreated patient antiviral million people danoprevir second december partner proximagen high level periostin reduction asthma past decade pegasy important generation hcv protease inhibitor develop develop novel oral small molecule inhibitor attack compare patient medicine treat patient hepatitis patient asian origin centre vascular adhesion protein vap celladhesion low level periostin companion test identify virus hbv roche continue explore way treat china collaboration ascletis phase molecule effective treatment high periostin level develop inhouse potentially lifethreatene liver infection study danoprevir combination pegylate inflammatory disease support physician personalise asthma therapy affect estimate million people rich interferon plus ribavirin show sustain viral hbv programme advance compound response patient certain genotype ophthalmology lebrikizumab phase trial treatment clinical development believe interfere subtype hcv research focus neovascular agerelate idiopathic pulmonary fibrosis ipf moderateto hbv different way promote antiviral response macular degeneration amd diabetic macular severe atopic dermatitis moderatetovery severe edema diabetic retinopathy glaucoma geographic chronic obstructive pulmonary disease copd atrophy glaucoma advanced form phase ipf study extend compare amd affect million people globally combination esbriet plus lebrikizumab develop world currently therapie esbriet approve fda grant fast track designation lampalizumab treatment addition evaluate erivedge treatment wong global prevalence agerelate macular degeneration disease burden projection systematic review secondary amd lampalizumab anti currently approve advanced basal cell carcinoma metaanalysis lancet glob health hanania lebrikizumab moderatetosevere asthma pool datum factor fab selective inhibitor complement abcc gdc additional molecule randomise placebocontrolle study thorax hepatitis fact sheet messina global distribution mediate inflammation potentially acquire esbriet intermune acquisition prevalence hepatitis virus genotype hepatology roche innovation innovation roche forwardlooke partnership genome sequence centre world sequence effectiveness difficulttotreat bacterial infection analyse ten thousand deidentifie dna novel lactamase inhibitor clinical trial therapeutic area potential expand spectrum multi mutual benefit collaboration drug resistant bacteria clinical development exciting collaboration andme programme track enable efficient analyse genome sequence datum trust collaboration partner approximately individual andme programme phase trial parkinson disease community immediate study treatment severe infection cause external innovation crucial strategy milestone roche strategy highquality family member find potential drug target enterobacteriaceae spp bring innovative treatment patient area healthcare datum advanced analytic improve disease currently cure unmet medical need currently manage development medicine decision partnership cancer immunotherapy partnership worldwide partner product patient care collaboration fmi infectious disease roche initiate number clinical contribute pharmaceutical sale roche acquire majority stake april roche strong legacy antibiotic collaboration study external partner pipeline compound externally leverage company strength advance antibiotic product develop roche list combine lead cancer immunotherapy drug source science businesssavvy partnering progress discovery development essential medicine list current atezolizumab broad number tumour team work closely internal gauge need personalise treatment cancer patient research strategy infectious disease focus type table gap standardise datum collectionanalysis clinical area high unmet medical need incidence trial setting clinical practice drugresistant infection create urgent innovation procurement time closely follow emerge demand new therapeutic option early pharmaceutical division build company globe academic advance collaboration include development roche meiji seika pharma fedora join force innovation centre excellence collaborate closely alliance opportunity screen companion diagnostic base nextgeneration tackle increase bacterial resistance antibiotic key supplier innovation innovation thousand potential partner year select sequence enable comprehensive genetic profil license investigational nextgeneration business case approve end versus truly help raise bar drug ing basis limited amount cancer tissue lactamase inhibitor compound target business case discovery development strategic agreement make fmi organisationally target lactamase enzyme combination launch initiation approach global roche pharmaceutical division new exist lactam antibiotic enhance roche partnering sign new agreement fmi retain operational independence foster include acquisition product transaction innovative energy entrepreneurial spirit research technology collaboration product outlicense agreement pharma biotech company come forward create gene genentech partner genentech research consortium genomics england announce new contract group sign new agreement include collaboration genome project clinical trial collaboration cancer immunotherapy include atezolizumab product transaction research accelerate development new diagnostic collaboration treatment patient disease investigational medicine external partner nonsmall cell lung cancer mutantselective egfr inhibitor rocilietinib clovis oncology molecular information dna analysis genentech partnering sign molecular triplenegative breast cancer colorectal immunotherapy talimogene laherparepvec amgen key deal capitalise emerge information collaboration help identify cancer liver metastasis tvec field molecular information rapidly evolve new drug target biomarker provide softtissue sarcoma cmb immune design role target medicine diagnostic solution insight likely disease renal cell carcinoma cdtargete antibody varlilumab celldex therapeutic collaboration establish foundation progress genentech human triplenegative breast cancer entinostat syndax pharmaceutical medicine fmi flatiron health mark longevity establish large human advanced solid tumour cpi corvus pharmaceuticals roche innovation innovation roche personal perspective exciting work patient report juncture match tumour profile target therapy ongoing trial genomics patient able continue active lifestyle medicine outcome positive deeply gratifying know work immediate impact cancer patient treatment involve develop decision support kim pelak phd data scientist tool help patient benefit methodology vast molecular foundation medicine information knowledge base example work report tool empower pathologist create report customise unlock cancer content patient majority patient report potentially actionablethey option treat physician genomic test roche clinical genetic code hope patient trial breakthrough cancer immunotherapy sequence tumour individual molecular information play key role identify novel drug target incredibly revolution genomic begin fascinate historically oncologist primarily interested exciting time work juncture genomics middle school scientist speak tissue cancer originate medicine grateful enormous potential personalised example breast cancer treat differently healthcarebut largely hypothetical colorectal esophageal cancer today know cancer drive today foundation medicine cut molecular malfunction potentially treat edge translate person unique tumour profile target therapy foundation personalise therapeutic option treat medicine test genomic variant patient cancer basis strategic genome regardless type cancer partnership roche chance impact sequence genome patient cancer work remember presentation female blood tumour tissue search genetic patient marathon runner prime life variant play role type cancer suddenly diagnose stage lung cancer curator sift huge database match bone metastasis colleague sequence finding target therapy include tumour find genetic variation datum contribute molecularly match patient study thousand ongoing clinical trial correspond target therapy treatment appropriate trial therapie roche innovation innovation roche basket trial umbrella trial brain ovarian skin lung bowel example glioblastoma brain tumour innovative approach new medicine new insight new procedure mutation cause different manifestation different medicine hit target realworld datum inform decision validate standardised information help basket umbrellas clinical trial design industry longheld stepbystep development clinical trial patient registry hospital researcher generate hypothesis improve new medicine combination medicine process traditional clinical trial healthcare provider insurance company patient outcome fully test broadly abandon linear timeconstraine protocol online health site smartphone app available era target therapy favour adaptive study design build explosion healthcare information molecular datum partnershipslike fmi usher new way perform study ability alter aspect ongoing trial base recent year add genomic datum generate sequence tumour dna cancer patient decadesold approach phase iii patient response new scientific understanding internally produce plethora andme sequence dna patient clinical trial give way cuttingedge study biotech company cheaply sequence parkinson diseaseare support research design realistically effectively allow parallel new clinical endpoint human genome short time relatively low cost focus help understand disease evaluate promise compound patient introduce assess impact investigational appropriately healthrelate realworld fundamental cellular level develop well target medicine example pathological complete datum rwd powerful resource provide therapy combination therapy patient response medication give prior surgery invaluable insight medicine disease highquality datum critical informing research pioneer study underway pathologist confirm vital cancer cell impact treatment time help design evaluate innovative firstofitskind basket study zelboraf find tissue sample take surgery clinical trial approach put metastatic melanoma braf status complete response confirm rwd vast complex varie mutationdriven tumour include brain lung colon approach show bring new treat dramatically quality reliability clinic todays healthcare landscape ovarian single studyor basketand allow ment strategy patient fast took capture manage analyse truly support demand holistic realworld information simultaneously evaluate zelboraf year herceptin approve research ultimately improve patient care lifecycle product increasingly reimbursement effective treat different cancer traditionally presurgical neoadjuvant treatment comparable nutshell drive science decision worldwide base new require separate trial tumour perjeta approval take year half healthcare company integrate rwd mean medicine bring add benefit standard type zelboraf currently approve metastatic ful way drug development care patient daily live regional melanoma cause braf mutation go strict medical focus look realworld datum science rwd group create cultural difference affect treatment impact patient firstever trial grow strongly year rwd different elderly rwd group help involve ambitious multipartner examine personal preference cancer therapy biostatistician vital collaborator address data gap question datum public trial test drug ongoing study compare patient team cull extract deliver relevant standardisation compatibility privacy umbrella tumour type glioblastoma herpositive early breast cancer common technology frontier leverage patient treat different medicine herceptin administer subcutaneously intravenously expertise pharmaceutical diagnostic include market pipeline drug strong relationship key industry base genetic mutation prominent whilst complex matter design new wave molecular datum support research partner want good advantage ocean tumour personalise approach innovative trial commit break informational opportunity swirl real increase probability treatment success ground drive datum generation accelerate help understand disease world datum young discipline believe provide invaluable datum target drug development right therapy rapidly crucial achieve optimal medicine good candidate specific deliver right patient cellular level patient benefit mutation approach upend roche innovation innovation roche innovation roche diagnostic minute subcutaneous tissue people sequence ng workflow talent diabete check datum need continue invest leading technology develop wirelessly connect receiver current glucose product ultimately integrate improve efficiency patient care value trend arrow glucose curve seamless endtoend sequence solution diary pipeline technology address point sequence workflow include sample preparation technology minimise number technology singlemolecule sequencer datum fingerprick need compare current standard analytic management tool test drugresistant organism utilise new reagent expert approach provide extensive acquisition geneweave provide roche diagnostic pharmaceutical division datum trend information particular importance recent acquisition kapa bioystem strengthen smarticle technology innovative new class work develop foundational multiplex programmable alarm person portfolio area sample preparation molecular diagnostic quickly identify multidrug technology translate new multiplex diabetes get alert glucose value rise fall foundation kapas technology custom enzyme resistant organism mdro assess antibiotic product opportunity strategy develop quickly essential people evolution technology allow generation susceptibility directly clinical sample modular technology accommodate wide able feel hypoglycemic enormous library enzyme variant need traditional enrichment culture sample range biomarker expression detect biomarker suffer socalled hypoglycemia unawareness ideal form enzyme rapidly select preparation process system development locate cellular compartment especially dangerous night expedite product development timeline vivodx fully automate randomaccess system nucleus whilst provide result timely affect significant number people diabete investment include signature diagnostic design rapidly meet need laboratory manner single specimen digital pathology insulin therapy lumora heat elution technology complement addressing mdro detection antibiotic therapy integral process image algorithm grow ng portfolio reinforce long guidance technology evaluate development critical rapid accurate clinical study innovative sensor term vision provide customer world multiple site interpretation complex stain pattern able demonstrate insertion wear comprehensive genetic testing solution sensor overall tolerate addition advance multiplex technology currently develop model immune panel result promise high level turn datum information era cancer immunotherapy view detect expression sensor accuracy precision especially actively explore opportunity increase need test biomarker foxp marker relate panel include hypoglycemic range diagnostic business area big datum inform clinical decision critical detection pdl work stream encompass include use aggregate diagnostic information detect multiple biomarker single slide darkfield plex brightfield plex assay nextgeneration sequence improve quality patient care preserve tissue context especially tissue format use unmodified modify primary acquisition partnership initiate research development efficient limit whilst conventional stain anatomical antibody amplify nonamplifie past year position develop good use big datum optimise business pathology typically limit biomarker detection scheme progress promise inclass technology nextgeneration laboratory develop series proprietary chromogenic provide customer bestinclass multi stains brightfield microscopy series plexe solution effective disease management fluorescent stain darkfield microscopy extend multiplexing capability addition increase continuous management diabetes number simultaneously detect biomarker newly develop continuous glucose monitoring reagent permit highly sensitive detection cgm system design provide ongoing glucose available research use use diagnostic procedure roche diabetes care summary clinical investigation report study colocalise bio marker critical identify measurement comprise glucose sensor ato freckmann performance evaluation continous glucose diabete sci technol zschornack tumour heterogeneity characterise immune remain body seven day controller evaluation performance novel system continuous glucose monitor diabete sci technol cell infiltrate receiver system measure glucose level wwwrochecomrndlocation wwwrochecomresearchtechnologie wwwrochecompipeline roche access healthcare access healthcare roche acce healthcare believe urgent deliver medical solution right develop innovation future commit work partner local level overcome barrier improve access test medicine patient patient group delegate country attend large patient organisation meet roche access healthcare access healthcare roche aim person need medicine diagnostic test able access benefit significant breakthrough diagnose treat tailor plan address implement disease improvement delivery successful partnership initiative healthcare steadily improve health outcome key area focus increase awareness increase life expectancy recent decade strengthen infrastructure improve affordability universal access medical innovation deliver innovation quality healthcare remain global challenge multistakeholder approach challenge complex multifacete healthcare innovative product deliver value resource demand resource vary therapeutic economic benefit example widely country country product healthcare delivery country region sophisticate new efficient improve mode admin medicine diagnostic test readily available istration reduce time patient spend whilst healthcare infrastructure hospital addition advance science lead limited basic medical care luxury personalise healthcare accompany diagnostic test identify patient likely believe critical uncover root cause respond specific medicine help limit access local level able optimise benefit patient ensure implement solution meaningful efficient use healthcare resource difference roll access planning framework result improve insight specific require playerspublic authority non regional national challenge local level governmental stakeholder patient organisation local community healthcare industry work closely whilst government establish partnership primary responsibility establish maintain healthcare system healthcare reinsurer local insurance industry play important role improve health global healthcare company roche share company improve cancer care responsibility tackle challenge improve health outcome million people china roche access healthcare access healthcare roche healthcare professional patient healthcare company quality healthcare share take global challenge responsibility improve access country country regulator policymaker rise chronic disease combine age sustainable solution tailor locally population grow unemployment economic onesizefitsall solution single pressure aggravate inequality access stakeholder tackle access challenge payer insurer healthcare lead poor outcome work partner continuously region world sustainably reduce barrier prevent limit people benefit product delivery quality healthcare complex involve number stakeholder work partner local level address challenge help impact cancer south east asia barrier include lack disease awareness establish sustainable solution example cancer big cause screen diagnosis fundamental infrastructure morbidity worldwide cause million death include adequately train healthcare professional decade global availability treatment adequate care cancer mortality predict occur low factor geographical political financial middleincome country half death cultural barrier effecting change occur south east asia incredibly challenging country patient journey receive optimal strengthen national cancer plan treatment map critical stakeholder shape effective way address burden cancer accord action asean cost approach tailor individual healthcare strategy tactic overcome hurdle national prioritisation integrate local oncology study region need country single topdown plan example poland cancer people experience death financial catastrophe approach provide comprehensive solution ensure sustainability approach plan treatment outcome poor europe year cancer diagnosis urgent action increase awareness disease healthcare option directly connect business link work partner include polish need protect population financial strengthen healthcare infrastructure partnership commercial strategy local management society oncology demonstrate need burden disease reduce impact loss local stakeholder improve availability annual goal focus building improve cancer care white book polish economic productivity affordability product local functional expertise strengthen engagement oncology report highlight gap treatment stakeholder dynamic healthcare environment access medicine trigger highlevel debate aim person need product see great engagement commitment ultimately ensure successful implementation stakeholder develop sustainable able access benefit creativity shape access plan potential access plan improvement strategy result ministry happen condition need place diagnostic medicine available healthapproved publication national include disease awareness adequate healthcare patient world follow global comprehensive cancer strategy represent infrastructure sufficient medical coverage rollout workshop develop major step forward cancer care country commit working stakeholder countryspecific access plan plan improve outcome access spectrum analyse hurdle encounter wwwrochecomaccesstohealthcare cancer factsheet iarc globocan estimate cancer incidence mortality prevalence worldwide kimman asean cost oncology publish george institute global health support unrestricted educational grant roche asiapacific regional office uicc national cancer control plan non governmental organisation eurocare european journal cancer roche access healthcare access healthcare roche africa strategy initial implementation nigeria ghana kenya cte divoire angola ethiopia gabon shift access paradigm africa ongoing outreach uganda senegal cameroon mauritius tanzania madagascar rwanda congo rdc congo mozambique tom principe equatorial guinea cape verde establish longterm solution africa strategy focus country aim increase access innovative treatment patient whilst create longterm sustainable business environment african continent develop quickly initial analysis decide focus gdp expect increase significant country stride improve health outcome country major challenge remain commenced strategy seven particularly subsaharan africa countries nigeria ghana kenya cte divoire roche cover remainder programme diagnostic test provide dried blood spot testinga angola ethiopia gabon implement aim treat additional patient viral simple innovative method collect transport poor outcome persist subsaharan africa wide selection activity collaboration local hepatitis woman breast cancer store patient sample resourcelimite multitude reason include low disease awareness partner include healthcare system strengthen year setting hiv global access programme expand late presentation patient disease limited local data generation advocacy healthcare commitment provide viral load early quantity poor quality healthcare institution prioritisation building infrastructure disease increase access hiv diagnostic infant diagnostic affordable price offering lack medical specialist uncertain supply chain management support awareness advocacy africa strategy build success country high disease burden primarily quality low government priority little local campaign treatment guideline education roche access programme effort africa prevalence datum limited funding market access solution healthcare improve hiv testing worldwide lead professional training private health insurance provider hiv viral load test roche long increase access viral load early infant million people hepatitis subsaharan local company pricevolume agreement stand commitment expand access hiv hiv testing help strengthen diagnostic africa whilst woman diagnose government diagnostic world capacity improve quality hiv treatment breast cancer estimate woman service help support global unaid die cervical cancer africa year breakthrough agreement cte divoire people live risk contracting goal ensure people receive committed improve outcome disease new case year breast disease access adequate prevention antiretroviral therapy achieve viral suppression area region cancer lead cancer woman cte treatment care improve laboratory capacity divoire case disease detect critical order ensure people live hiv programme run partnership take holistic approach cancer advanced access diagnostic test monitor joint united nations programme hivaids africa strategy overall strategy hepatitis cause liver cancer treatment need clinton health access initiative unitaid analyse access barrier countrybycountry country prevalence president emergency plan aid relief basis develop tailor solution local partner january launch hiv global access global fund fight aid tuberculosis malaria aim increase access innovative treatment roche commence new programme programme offer sustainable solution hiv patient subsaharan africa whilst create partnership cte divoire ministry health viral load test eligible low middleincome seven million infant longterm sustainable business environment improve access test innovative medicine country programme cover country conduct indepth analysis country africa comprehensive approach roche support close global population people hivteste roche multitude factor disease incidence government raise disease awareness train infect hiv programme urban population growth middleclass emergence healthcare professional build diagnostic cover early infant hiv testing timely hiv infant diagnostic global access programme healthcare spend government focus healthcare capability treatment patient pay diagnosis greatly improve disease management minimal portion cost government outcome hivinfecte infant roche early infant afdb oecd undp african economic outlook cervical cancer fact sheet islami tumor size stage breast cancer cte divoire republic congo result populationbase cancer registry breast yoman occult hbv infection untreate hivinfecte adult cte divoire antivir ther roche access healthcare access healthcare roche personal perspective think strategy increase local expertise roche provide scholarship medical oncologist additional year diagnostic division example instal tissue diagnostic machine public cancer treatment centre additionally provide training pathologist technician life mean commit assist ministry health gathering accurate data cancer cancer registry development partnering support training provide infrastructure include beatrice nyawira laptops software good datum provide clear picture actual disease burden inform policy medical manager roche kenya resource allocation addition partner government public healthcare programme increase access reduce access innovative breast cancer medicine low month develop country year think come cancer finally barrier kenya additional year life mean woman get voice medium advocacy raise child start new career realise government open willing act dream difficult value commitment come well time medical doctor feel deep word truly believe huge difference need help people see patient day improve cancer treatment kenya year realise ability roche kenya partner government impact overall healthcare environment break access barrier oncology treatment limit join roche go price drug awareness diagnosis increase capacity today colleague working expertise healthcare professional treatment fundamentally change treatment paradigm access look continuum oncology whilst infectious disease hiv malaria tuberculosis remain priority programme offer africa cancer receive attention scholarship additional medical oncologist deserve kenya sponsor programme train oncology nurse local medical school eldoret particularly breast cancer incidence rate conduct preceptorship local international approach western countriesbut expert improve mastectomy diagnostic mortality rate high life expectancy technique cancer diagnosis leverage forge new partnership change paradigm kenya breast cancer patient diagnosis collaboration pharmaceutical diagnosis treatment breast cancer roche access healthcare access healthcare roche personalise reimbursement model framework work healthcare system multiple indication pricing combination pricing pay response allow medicine price accord ensure benefit combination therapy basis level reimbursement patient increase access test medicine benefit deliver different indication reflect whilst take consideration limit response medicine specify time period healthcare budget approach allow price differentiation reflect benefit treatment deliver patient bring product market work closely determine appropriate payout treatment government insurer healthcare launch affordable cancer insurance policy provider determine value enable cover well available treatment access demonstrate value product patient hospital doctor cancer education family healthcare professional payer society support approximately million policy palliative care partnership likely trigger france base indication line treatment general order gain appropriate reimbursement sell china similar arrangement come month duration treatment treatment combination add choice national health recognise despite improvement october roche sign contract personalise reimbursement model authoritie wide range potential pricing healthcare infrastructure funding innovative large insurance company shenzhena city whilst reimbursement today base solution discuss roche ultimately medicine diagnostic remain reach population million peopleto ensure avastin undifferentiated price item personalise benefit patient patient need explore reimbursement list metastatic colorectal reimbursement model prm allow medicine new pricing access model tailor cancer shenzhen city price accord benefit deliver wide spectrum innovative pricing model dynamic healthcare system china roche target therapy develop innovative pricing uniform pricing structure innovative approve country mabtherarituxan prm framework include multiple indication model tailor need patient different approach include personalise reimbursement avastin herceptin tarceva reimburse pricing allow medicine price accord healthcare system example international model differential pricing patient assistance roche aim significantly increase patient benefit deliver different indication differential pricing programme help reduce programme private insurance coverage access rate china herceptin mabthera combination pricing benefit combine price government facilitate reimbursement rituxan year therapy reflect whilst take account budget medicine prescribe public healthcare government emerge develop region constraint pay response reimbursement system price base adjusted gdp find increasingly difficult fund access new access initiative europe base patient response medicine capita country question roche believe innovative treatment cancer disease portugal budget constraint specify time period price differentiation country public budget roche actively support public sector access innovative improve patient access innovative medicine innovative approach improve treatment coverage treatment national system prm introduce europe market significant access problem include private insurance complement increasingly difficult roche investigate publicprivate market take example france public funding healthcare partnership start work initiate pilot phase hospital develop region sell second brand important health insurance company country validate feasibility prm approach breast product subject quality expand private insurance coverage china expand insurance company coverage help cancer treatment scale initiative control original product different china small portion population close funding gap significantly hospital name slightly different form health insurance policy cover cost cancer france take vial syringe additionally treatment roche team reinsurer october health insurance market leader patient assistance programme help provide access local insurance company include introduce firstever private health scheme different pricing model base value medicine underinsure large help develop policy cover cancer portugal cover entire spectrum patient consider country uninsure patient cancer treatment care enable company care monitor disease treatment roche access healthcare access healthcare roche partnering key stakeholder elevate patient voice organise harnessing power woman drive positive change oncology panel discussion world cancer leader summit find equitable sustainable solution focus societal value innovation global barrier healthcare achieve policy level help facilitate persistent commitment action conversation measure value new improve cancer care access outcome people affect multiple sclerosis develop multiple stakeholder succeed jointly innovative treatment climate cost constraint member society support platform multidisciplinary group expert support develop innovative sustainable way bring effective limited healthcare budget european develop report woman change agent educational grant roche present affordable healthcare people improve health forum gastein lead health policy confer oncology explore reduce european committee treatment research health outcome ence hold interactive session collaboration burden cancer woman add value patient multiple sclerosis recommend policy european health association healthcare system society change ensure people disease underline importance promote good topic session scoping value innovation able receive effective treatment early health globally sustainable development measure unmeasurable attract wide range increase collaboration patient group impact lifelong course disease goal roche support stakeholder level health system patient engagement seriously roche recommendation report detail key achieve goal ensure endeavour support patient organisation endorse number professional association universal health coverage include access clear value analysis objective possible today interaction advocacy group healthcare service medicine vaccine people account price innovation patient group multifacete range live develop develop region clinical outcome consider broad funding organisation building capacity support patientdriven idiopathic impact family communitie employment organise meeting support advocacy pulmonary fibrosis ipf charter call roche join stakeholder economy detail decisionmaker action improve ipf support drive universal health coverage patient quality life support welcome trend evidence value reduce burden cancer society international experience exchange patient development longterm treatment work base decisionmake resource allocation key theme world cancer leader organisation ieepo roche large global patient cure lowresource setting crucial target limited summit join leaders united organisation meeting hold munich health budget intervention service nation agency national ministries health patient focus vital role patient organisation establish preapproval access provide benefit value organisation academia private industry record total delegate country medical ethic group office great number people organise harnessing power woman attend ieepo agree potential chief medical officer focus ethical drive positive change oncology panel role patient play research clinical trial design patientcentre approach clinical research respect health technology assessment hta discussion investigate direct indirect recruitment hta aspect drug preapproval access investigational medicine key tool help country allocate burden cancer impose specifically woman development access increase go forward aim increase valuable health resource efficiently equitably role family member caregiver patient significantly exchange hope incorporate patient base evidence support affiliate perspective define potential value new understanding approach good panellist explore way harness grow international report brain health time matter innovation bring people life ensure optimal access innovative treatment political power social scientific prominence multiple sclerosis aim improve outcome local level woman ensure policy prioritisation action wwwrochecomstakeholderengagement european cancer league european health management association international association mutal benefit society european patient forum wwwrochecompatientgroup giovannoni brain health time matter multiple sclerosis publish oxford pharmagenesis ltd funding educational grant roche ipf patient advocacy group european ipf patient charter initiaitve support roche roche responsible business responsible business roche pon sible sine compliance license operate serve foundation build maintain trust stakeholder supplie audit conduct global local level roche responsible business responsible business roche commit improve life nearly year lead spirit run business socially responsible way united nations general assembly issue like yearly sustainability forum unanimously adopt sustainable development internal stakeholder external goal sdgs end poverty protect planet expert discuss innovation supply chain ensure prosperity foster access healthcare improve sustainability sustainable development agenda agreement report affiliate level enhance mark important milestone phase employee engagement example roche site like sustainable development engagement mannheim penzberg basel introduce wide range stakeholder platform employee contribute idea improve work environment process commit support number half employee mannheim penzberg sdgs line business strategy particular work continuous improvement sdg aim ensure healthy life activity additionally employee submit promote wellbee communicable idea lead saving eur million disease tuberculosis malaria non mainly result waste reduction pharma communicable disease include cancer mental diagnostic manufacture general disorder universally recognise area optimisation manufacturing logistic high unmet medical need forefront develop effective therapy diagnostic tool compliance license operate diagnose treat monitor cancer neurological responsibility seriously order disorder detail objective meet high standard business ethic integrity sdg achieve universal health coverage instrumental sustainable success prerequisite achieve well access safe ability lasting impact effective highquality medicine diagnostic public health integrity roche mean thing test develop innovative approach right start strongly believe people collaboration international local player important success factor compliant strive break access barrier behaviour start line manager right patient world support universal mindset responsible careful healthcare coverage goal detail selection instruction monitoring team compliance go line management stakeholder engagement key pillar roche employee accountable comprehensive sustainability management process behaviour approach form foundation allow identify prioritise material comprehensive compliance management system wwwrochecomstakeholderengagement roche responsible business responsible business roche group risk report annually foster culture compliance supplier service provider finding sustainability employment contract terminate expectation employee express audits category ground unethical behaviour agreement discuss executive management roche group code conduct design business partner terminate set standard business behaviour reason provide guidance employee ethic launch revise roche group code conduct labour manage opportunity risk assess sustainability risk opportunity help foster awareness health safety risk management policy set approach establish business sustainability risk integrity utmost importance organ environment identify managing report internal process allow assess emerge risk isation addition new version elearne managementsystem external risk opportunitie group risk development annual basis integrate course support good record management practice management process embed level exist group risk management audits conduct range provide indicate percentage introduce record management finding category roche help supplier follow organisation consistent methodology process year emerge sustainability risk component roche code conduct define finding process routinely perform risk assessment development identify assess create manage retain discard record group risk report cover material risk expert crossfunctional team new category accordance law regulation speak right thing annually discuss corporate executive identify consider include country operate training module primary goal create environment committee review audit committee appropriate previous year emerge risk mandatory employee businesscritical mutual trust issue discuss open board director development contractor dialogue potential violation prevent employee encourage speak group risk advisory team provide advisory digital evolution company roche supplier service provider expect compliance concern available speakup service site affiliate project product team dependent cuttingedge information adhere standard employee channel employee roche group facilitate risk discussion support business technology digital datum raise roche supplier code conduct include speakup line available language specialist area digital medium question datum integrity datum confidentiality contract offer elearne programme country employee raise compliance security compliance sustainability elearne cyber threat cloud security consider help supplier service provider increase concern good faith act interest roche programme classroom training workshop risk innovation constant evolution life science knowledge understand roche expectation deserve acknowledgement roche tolerate roundtable crossdivisional risk forum technology require company adapt industry standard retaliation employee raise place improve understand risk help innovation strategy order constantly embrace compliance concern good faith employee manage appropriately scientific progress business opportunity operate stringent process qualify corporate evolution global corporation expose audit current new supplier service provider chief compliance officer receive continue strengthen business continuity grow complexity business environment conduct audits report relate alleged violation code management bcm ensure site include increase number thirdparty global local supplier service provider conduct business ethic incident reporting affiliate respond effectively catastrophic event relationship partnership main finding supplier relate quality health system vast majority report relate develop strategy tactic deliver minimum government society company safety whilst finding service provider occur personal integrity case expense fraud conflict acceptable level key product service group include multiple stakeholder decision primarily quality social managerial area interest abuse company asset harassment bcm policy guideline facilitate consistent making process include government non help supplier follow finding discrimination remainder relate violation align approach local implementation governmental organisation citizen group company integrity good practice marketing demographic evolution company challenge antitrust false record allegation prepare influenza pandemic cover rethink adapt operating model fit societal roche group code conduct unfounded investigation group influenza pandemic policy base expectation need flexible workplace found allegation subject recent interim guidance site available different language careful investigation allegation found require update influenza pandemic adequate corrective measure sanction take plan place properly test wwwrochecomcodeofconduct wwwrochecomrochesuppliercodeofconductpdf wwwrochecomsupplier wwwrochecomriskmanagementandcompliance roche responsible business responsible business roche working government improve public health increase transparency actively engage government official commit transparent reporting industry body order contribute endeavour drive social environmental public debate development effective performance diligence financial public health law regulation policy performance follow global key area discussion engagement reporting initiative guideline disclose future bring new challenge opportunity base development disruptive information technology core application level report number data protection regulation vitro additional indicator diagnostic regulation access innovative medicine patient organisation important partner biosimilar payment reform patient roche interaction commit separate commercial medical publish datum voluntarily global level access healthcare ensure collaboration reflect share organisation pharmaceutical sustainability reporting value integrity maintenance independence diagnostic division differentiate clearly roche remain independent political affiliation respect mutual benefit support patient nonpromotional activity medical scientific contribution healthcare institution support number association organisation base write agreement intent promotional activity addition total chf million political institution switzerland spend clearly state purpose separation establish pharma healthcare chf million include payment financial support include description compliance office effectively support line manage industry association chamber significant indirect nonfinancial benefit ment compliance responsibility education healthcare professional commerce financial assistance trade union research donation political party cantonal accordance industry guideline roche dedicated engage productive education patient general public federal level donation political party public detail relationship patient transparent dialogue collaboration healthcare lowdoubledigit thousand swiss franc range organisation list update annually professional healthcare organisation disclose clinical information benefit society overall total contribution publish website commit satisfy legitimate request roche commit share datum clinical trial donation information result research take significant step recent year contribution patient organisation development activity transparent accurate enhance share clinical study information eligible employee personal total chf million timely way political contribution roche good publishing protocol study result information government committee ggc genentech new divisional guidance clinical trial registry political action committee genenpac research project implement interaction healthcare disclose appropriate clinical study voluntary political action committee workshop seminar meeting professional organisation include grant documentation clinical study report csrs ggc genenpac jointly contribute approximately educational grant sponsorship donation healthcarerelate peerreviewe publication presentation usd candidate candidate committee service contract patient organisation entity train information session provide qualified researcher access disease awareness general education organise train employee group patientlevel clinical trial datum new guidance case disclosure safeguard transparent contribution patient privacy collaborate number healthcare professional organisation group involve advance opportunity datum commit compliance law share engagement include partnership regulation industry code require disclosure establish clinicalstudydatarequestcom sunshine act efpia disclosure code transcelerate wwwrochecomnonfinancialreporting wwwrochecompatientgroupslist wwwclinicaltrialsgov httpseudractemaeuropaeu wwwclinicalstudydatarequestcom roche responsible business responsible business roche personal perspective compliance ask make decision right thing need additional clarification help compliance resource regional policyit global level compliance policyit mindset ask make mindset decision right thing mindset organisation launch compliance champion initiative evolve compliance journey create environment spend time evaluate potential compliance issue ameya telang finance director impact external stakeholder compliance officer roche philippine doctor ask spouse partner attend roche event example politely decline explain term integrity standard integrity basis strengthen position reputable company govern interaction doctor hospital administrator patient stakeholder believe strongly patient business roche job direct influence take job need discover develop new drug deepen understand compliance healthcare contribute make business sustainable truly grow roche father regulation internal guideline matter work company year evolve rapidly question ambiguity impress roche value arise people need information resource close hand today believe firmly roche value work roche philippine finance director establish compliance champion responsible meeting objective compliance philippine function officer job ensure sell product pharmaceutical diagnostic diabetes care ethical manner rely science compliance champion contact person clinical datum product convince decision easy colleague consult maker value catalyst change organisation pharmaceutical industry highly regulate employee long look compliance separate roche go regulation ensure function daily work internal employee compliant high ethical standard expertise help illuminate grey area work compliance champion function embed area healthcare compliance standard proactive address potential issue proactive thinking daily work roche responsible business responsible business roche put patient safety distribution channel combat reduce animal testing minimum counterfeiting market strengthen legislation like researchbased healthcare company roche conduct animal test require regulatory continuously improve safety standard council europe draft convention authority test result constitute time bind international achieve scientifically acceptable alternative instrument criminal law field counterfeit animal testing use invest medical product similar crime involve significantly development testing method threat public health medicrime convention computer simulation isolate cell grow ensure patient safety effectiveness roche internal quality compliance audits convention come effect january petri dish switzerland support product priority collaborate regular basis ensure compliance good research foundation fund development regulatory agency monitor report adverse event manufacturing practice standard approx initiate programme roche increase improvement method base strategy experience patient communicate imately inspection conduct health security supply chain implement replace reduce refine product safety activity authoritie roche manufacturing site focus number new technology include overt proactive corrective preventive action address covert anticounterfeiting feature barcode animal internal product wellcharacterise benefitrisk nonconformity determine cause mass serialisation technique tamperevident research number animal contract profile update life ensure sustainability operation package completion programme slate research organisation cro work roche product adverse event store global datum roche product folding box case behalf increase approximately base review qualified physician report quality system instrumental maintain pallet unique identification animal mouse rat major site promptly appropriate regulatory authority right operate overall successful health award continue reaccreditation status require addition communicate openly authority inspection health authority interaction define regulatory framework biosimilar association assessment accreditation regulator stakeholder require system enable timely approval order ensure safety patient develop laboratory animal care international underscoring employee immediately report drug safety new product correspond successful pre ment manufacture biosimilar monoclonal commitment ensure animal welfare quality issue respective safety personnel approval inspection antibodie subject rigourous clinical employee complete mandatory programme regulatory standard postmarkete total number animal research year ensure awareness adverse roche pharma technical operation unit pharmacovigilance protection roche cro decrease event report tasked ensure availability roche medicine worldwide maintain quality plan roche support development regulatory medicine leave manufacturing process foundational operation quality framework introduction biosimilar meet highquality standard roche manual highlight key action continually improve actively engage stakeholder dialogue pharmaceutical quality system process comply overall quality compliance standing framework help ensure consistent high level ich guideline develop accordance ich guideline routinely share public health protection respect biosimilar process scientific consensus regulatory roche senior management discuss whilst protect innovation originator industry expert work quality global health authority product firmly believe regulation management system inspect annually relate biosimilar impede relevant health authority worldwide fighting counterfeit globally promote incentivise innovative research manufacture distribution counterfeit novel medicine medicine diagnostic product criminal cro roche require employee immediately activitie threaten safety patient roche collaborate government healthcare professional report drug safety quality issue regulatory authority police customs services international council harmonisation technical requirement pharmaceutical human use wwwrochecomanticounterfeite roche people people roche people roche commit cultivate diverse talent pipeline generation geographie functional area expertise pillar make roche great place work awardwinne employer year year key senior position lead people establish develop region experience roche people people roche ee science innovationdriven company distinguish roche people commit provide well possible working environment thrive roche start foundation respect cultivate diverse talent pipeline passionately believe company perform diversity inclusion vital foster innovation high level maintain care encourage different perspective idea respectful working culture take genuine interest thinking style business different people fundamental thatif division world need people right fall place understand difference inclusive culture help encourage accept leverage diversity continue focus foster strong inclusive help ensure lose access internal leadership culture building diverse external talent talent pipeline help people company excel everchange business environment define diversity inclusion mean formalise diversity inclusion roche consistently recognise practitioner network ensure leader good company work honour align way bring commitment life award roche include placement workplace great place work list include fortune good company list work mother magazine develop future leader good company list diversityinc introduce countryspecific employee value noteworthy company proposition reflect important priority employee site world reflect diversity aspect business example observer panel provide global development highpotential programme ensure diversity assess future leader programme leader address current future business challenge roche group need inspirational leadership aspect diversity include generation gender geographie functional area expertise diversity refer wide range visible invisible difference exist people inclusion refer proactive behaviour create environment people actively include roche people people roche leadership commitment firmly believe person genuine interest people roche deserve great leader listen carefully tell truth explain day strive lead take genuine interest people empower trust people decision example consistently discover develop potential people commit strong leadership demonstrate value strive excellence extraordinary result integrity courage passion set priority simplify work commit increase representation facilitate international assignment allow congratulate people job key leader establish develop region employee gain essential experience experience provide opportunity roche employee international assign employee work different environment ment total assignment commit increase representation develop region woman key leadership position progress goal woman accounting diversity pharmaceutical diagnostic accelerate movement talent particularly kiswahiliis programme roche leader leader key leadership position pharmaceutical division instigate develop region tanzanian healthcare sector leader combine management overall leadership acceleration programme new initiative leadership development social impact photo design advance talent specific develop leader attend global leadership set target talent scout build region ensure multiyear diversity development programme include initiative external pipeline increase representation inclusion plan lead business sponsor lead leadersroche lead people significant briefing market access woman people establish develop organisation roche addition leader receive compliance leadership group approximately region experience detail feedback review employee roche leader travel tanzania work diagnostic division sponsorship programme provide feedback leader partnership local ngo address real healthcare woman key leadership position woman run successfully challenge country improve cervical year expand include highpotential nearly leadingroche participant report cancer outcome compare woman switzerland people develop region experience positive change month state woman tanzania times likely initiative member senior leadership team daily working practice closely align die cervical cancer disease largely preventable sponsor talent leadership commitment important early detection participant manager observe increase roche deserve great leader strong leadership skill month particularly leader find experience hugely leadership culture critical nurturing engage increase selfawareness leadership impactful term grow leadership work environment people want come management behaviour skill team ability identify practical woman key leadership position goal work stay longterm solution address challenge ensure long lead change world term sustainability programme local want leader understand aspect foster strong leadership culture successful leader know impact participant continue support project key market business compliance continue embed leadership comfort zone progress partner remotely hand governance people culture experience commitment recruitment selection launch new leadership initiative focus group roche leader suggest take year live feedback performance management building skill set njiawhich mean path work country start continue skillbuilde programme core understand culture competency enhance leadership skill employee identify potential leader wwwrochecommateriality world health review wwwworldlifeexpectancycomworld healthreviewswitzerlandvstanzania roche people people roche personal perspective need diverse people happy engaged experience work productivity increase significantly way thinking arrive primary task successful integrate previously independent research roche global organisation effort shanghai focus infectious disease especially hepatitis virus integration align strategy broaden pipeline talent stella phd site head roche structured performance management career development process build customise innovation center shanghai plan wide range training help people grow professionally offer job rotation country leadership role time reacclimate chinese result initiative employee language change internet age shanghai engagement score internal survey know impact highenergy cosmopolitan city mix geo jump culture reflect diversity roche people happy engage work innovation center productivity increase significantly role roche bridge east west science leader motivate kind management changsha capital convince purely american swiss impact hunan province interested science chinese way produce good result early age study biophysic beijing immensely complex task drug development receive scholarship phd molecular gender ethnicity nationality need biology immunology remember diverse experience way think boarding plane suitcase successful background help work dollar pocket culture function china employee reluctant speak meeting accustomed finishing degree work drug decision practice inclusive discovery scientist behaviour create safe environment strategic consultant join roche manager bad question encourage people return china establish active role find solution lead team roche partnering shanghai office join pre researcher scientist give credibility site head roche innovation center expert subject try shanghai nearly year abroad take big picture mind ask right question communication key join team member lunch support team perform well listen concern roche people people roche half employee support prepare workplace future attract retain good talent minute hire candidate base jobrelate change application roche group candidate evolve meet everchanging need attract excellent reputation great place work drive unique culture strong purpose success excellence site site include discount science employment benefit buy roche nonvoting equity security pension global development opportunity scheme health insurance childcare onsite fitness fully support fact people aspiration need workforce essential medical facility flu vaccination preventative change evolve different stage life ensure individual feel value respected key focus prepare workplace health screening discount local retailer career business environment change team feel benefit vast range future find talent early career transportation workplace take account contractrelate change perspective experience apprenticeship scheme graduate trainee half employee support job programme launch new initiative flexible benefit programme tailor relate change workplace oftenuse phrase truth help recruit identify great potential individual need example site future workplace herewe early stage development come implement flexible benefit programme provide opportunity employee wait implement change year focus extensively attract employee prioritise certain reward experience different role company offer wide range attractive benefit develop talent pension company car month purposely nonformalise generation include flexible work environment arrangement condition entry allow country stateoftheart technology proactive inhouse approach recruitment second year applause employee gauge interest space business area globally align group internal talent scout programme online tool employee business fully commit roche focusing recognise directly ecard focus reflect increase mobility build external pipeline meet future need reward point nomination overall usage prepare workplace future staff provide access roche work cover gap prioritise succession planning role peer year environment anytime support difficulttohire current role topeer recognition employee employee millennial people today device build common information approach significantly contribute reduce early mid time solution chris connect employee line dependency external recruitment agency easy access individual benefit generation workforce manager professional roche expand availability similar different need understand offer broad set selfservice continuous key target roche improve totalreward statement online selfservice entire candidate experience undertaking allow employee overview significant improvement increase ease compensation benefit unique application review entire candidate online resource packaging employee people fiveyear goal experience pre postapplication ensure individual tailor benefit december baseline candidate find process straightforward respectful welcome service available total employee switzerland germany china quartile rewarding recognise employee live country follow try strike balance highly competitive selfservice solution far base salary performancelinke reward view rate employee increase representation increase representation rank overall employee numerous benefit employee vary woman key leadership role people establish engagement score measure develop region experience global employee opinion survey calculation base working day year eighthour working day wwwrochecomemployee key leadership role roche environment community environment community roche env ironme community aim minimise ecological footprint increase use renewable resource whilst continue expand global business seek support local community longlaste partnership stainable track goal sustainable energy consumption roche environment community environment community roche continue improve environmental performance significant progress improve energy efficiency safety security health environmental protection identify area improvement recommend form central operation change database good practice important component sustainability approach employee frequently share knowledge exchange commitment businessrelate new idea conduct regular training session activity strive continuous improvement regional conference workshop provide possible monitor performance regularly online tool local language help employee ensure compliance high standard foster engagement responsibility objective ensure process equipment employee participate approximately stateoftheart importantly devote special hour training average attention prevention key effective hour employee management roche site invest stateoftheart energyefficient infrastructure ensure compliance foster improvement investment allow reduce environ policy audit chemical pharmaceutical mental footprint reduce cost diagnostic manufacturing facility periodically increase frequency accord exist risk improve monitoring performance roche group perform audits company global production operation roche audits assess performance expose risk possibly damage people legal compliance internal standard stipulate good environment reputation audits future improvement plant management local consulting training environmental protection officer conduct frequent check occupational health safety professional inspection assess compliance standard risk management minimise risk safety expect contract manufacturer supplier health environmental protection employ service provider meet standard people worldwide people security expert ensure compliance thirdparty auditor team roche site identify risk develop manage inspect operation supplier mitigation plan communicate policy recommendation improvement guideline employee stakeholder event noncompliance terminate motivate implement necessary measure contract refuse renew ask improvement effectiveness management system actively support review frequently employee encourage wwwrochecomenvironment measure performance base set key performance indicator kpi aim reach kpi wwwrochecomourshegoalsandperformance roche environment community environment community roche addition spending chf million occupational health safety employee handle substance travel tracking tool identify assist roche environmental purpose investment safety priority believe define necessary measure need know business traveller case emergency operating cost safety security total job urgent routine potencytoxicity substance level trip new tool operational chf million safely primary objective roche exposure cause operation year accident rate rar number work day roche assess establish level acceptable second security focus set managing material topic lose occupational accident employee exposure substance exposure level asiaafrica security workshop hold shanghai constantly aware material issue year lose time accident rate ltar determine systematically ensure site security officer asian site regularly gather information concern sherelate number accident cause absence exceed establish standard protection select african affiliate discuss challenge risk opportunity roche affiliate work work hour low possible overexposure ensure engineering control good practice key topic region consult listen stakeholder group continually improve occupational new process design fulfil criterion prevention response counterfeiting match stakeholder issue health safety measure set feasible exist one modify large extent product information security include risk internal strategic priority risk framework ambitious goal establish health meet current standard containment intellectual property measure protect produce materiality matrix safety committee virtually roche site engage train adequate security measure small able identify material topic stand technical activity site fire process safety affiliate new group directive issue area interest group stakeholder accord risk level wellestablishe fire safety survey guidance conduct security investigation topic actively manage group perform extend related confirm criminal activity roche include limited climate change energy tenyear goal rar additional site survey survey productscounterfeite diversion theft resource occupational mental health ltar introduce new goal carry member insurance group water roche consider material issue reduce number vehicle collision million professional thirdparty fire engineer employee health safety order strengthen environmental strategy kilometre year implementation recommendation follow know material issue goal reach fiveyear objective keeping rar auditing system new project want achieve able develop clear ltar accident rate require fire protection installation benefit define process create progress target low single accident result long absence professional fire engineering knowhow available setting initiate action plan midterm target lead fluctuation rar key figure roche establish process safety network set new goal occupational accident profile remain consistent chemical production site meet regularly feasible challenging area people slip trip fall repetitive strain represent work common issue concern share good environment business reflect majority workrelate incident practice recommend improvement similar sustainable development goal adopt network pharmaceutical solid formulation site united nations detail prevention overexposure substance initiate powder handle workshop cornerstone protection health roche solid formulation manager officer hold process safety management directive develop issue fiveyear goal base figure security protect employee physical asset critical information integrity brand product principal concern roche preventative illness rate accident rate measure priority aspect security losttime accident rate number workrelate accident focus implementation global working day lose year accident ecobalance energy consumption water consumption general waste roche environment community environment community roche emission water primary energy roche emission air ecobalance landfille waste conduct operation sustainable way water consumption leverage modern technology noise research pharmaceutical diagnostic competition trigger significant improvement manufacture dependent natural resource line sustainability strategy increasingly scarce internal stakeholder opportunity contribute commitment sustainable development idea suggestion improve sustainability ecobalance holistic way measure impact emission air contribute positive effect proactively seek employ new sustainable culture performance raise awareness consumption energy resource despite increase number employee technology process minimise environmental protection encourage sustain emission byproduct waste impact environment roche depend ability identify cost saving environmental business activity impact environment today large proportion energy roche nonrenewable resource vulnerable protection activity ecompetition submission different way measure total impact come fossil fuel nonrenewable deplete supply constraint volatile market price result significant improvement variety ecobalance metric point system allocate source oil natural gas result area include energy conservation waste reduction ecologically relevant parameter develop produce greenhouse gas ghg mainly proud sustainable development decrease consumption water raw material swiss federal office environment waste product contribute climate change achievement recognise externally reduce air pollution compliant late guideline metric air pollution aim maximise efficient dow jones sustainability index rank roche provide global view impact energy usage increase use sustainable industry leader environmental category win suggestion generate earth ecosystem point add energy whilst continue expand global business high mark climate strategy environment monetary saving chf million relate total number employee policy management report operational eco start programme estimation enable monitor environmental share sustainable energy actual datum goal efficiency effort notice newsweek base size initiative year impact employee strategic fiveyear goal rank roche green company onyear cost save potential reduce ecobalance allow world large publiclytraded company local site management freedom develop locally market capitalisation improve energy efficiency appropriate strategy objective reduce set energysave action plan environmental impact local level latvian sustainability index site include implementation organised institute corporate sustainability innovative technology continuous upgrading ecobalance comprise responsibility give roche silver award roche infrastructure improve energy efficiency emission air compare goal uruguay recognise effort purchase energyefficient equipment include hybrid total environmental impact employee create sustainable work environment car review employee travel need decrease nonsustainable sustainable award silver leed certification sustainable change work process complex task design lee commercial interior rate highly regulate facility work effort optimise energy consumption system focus efficient use water steady transition sustainable energy reduce volume consume water energy use leedcertifie recycle total project complete energyefficient material equipment yield reduction approximately tonne emission estimate cost save lee leadership energy environmental design popular green building certification programme swiss eco chf million year factor ecological scarcity method roche environment community environment community roche oil natural gas car fleet energy use type air travel reduce energy intensity grid electricity replace fossil renewable energy waste district heating recently set tenyear goal consumption increase sustainable reduce energy intensity gigajouleemployee energy use absolute term energy consumption facility scope purchase energy business flight slightly increase consume scope fly headcount remain stable thank assessment valuation impact dependencie organisation include new building inaugurate expect reduce energy consumption employee increase employee awareness video company operational site switzerland south san francisco basel approximately compare baseline level conferencing tool helping stabilise key objective determine approach additionally plan increase proportion businessrelate travel add value comparison exist methodology genentech new building south san francisco sustainable energy absolute use design provide optimal working condition terms energy consumption increase videoconferencing alternative business travel operate energy standard remediation activity nutley sustainabilitya key parameter new office building receive lee site increase production headcount framework roche energyefficient gold certification project sale grow decouple energy consumption building focus criterion highly reflection dual effort genentech energy growth business energysave functional highly sustainable high efficiency expert nearby lawrence berkeley activity result decrease car fuel quality urban design architecture roche bring flexlab laboratory flexlab test bed vast array practice technique assess optimise building operation energy consumption terajoule skill energy consumption minimum realworld condition test configuration measure reduce operate energy heating wall window light shade heating usage videoconferencing hour power equipment integrate ventilation air conditioning total scope fly kmheadcount conceptual phase finish scope structure reduce operate energy consumption basel new datum centre open energy natural capital building design air leakage expect consume energy average scope multinational company currently build reduce include high new european data centre roche basel new consumption conduct detailed pilot test inform develop performance window extra insulation wall build highrise inaugurate september gjemployee ment new natural capital protocol aim ceiling floor addition effective window earthquakeresistant highly functional scope internationally agree harmonised approach placement provide natural light reduce sustainable topquality workspace flexible business flight business systematically account need electric lighting day layout allow approximately employee energyintensive monetary value environmental impact approach apply new facility global utility dependencie decisionmake andor reporting pilot assessment begin explore datum collect group ompresse air liquid nitrogen overall relationship environment value chain addition involve detailed growth rate report constant exchange rate average roche environment community environment community roche personal perspective contribute great feeling look build building know realisation onceinalifetime water remain constant temperature opportunity degree celsius cool building summer pillar energyefficient operation sensor workstation detect markus wllner present turn light ventilation automatically monitor system senior technical project manager building track energy usage employee encourage think green term reduce environmental footprint high standard inauguration ceremony hold september profession construct possible passion magnitude onceinalifetime opportunity sustainability teamwork particularly proud building view site development plan look term sustainability especially forward build great experience energy efficiency priority take role responsibility year engineer project senior management new project manager roche take increase level responsibility roche new highrise office building pillar sustainability minimise energy basel building height metre use instal lead light floorswa big challenge efficient highefficiency fluorescent lamp led need change team responsible technical year average significantly reduce installation build automation operating expense waste example minimise energy use innovative faade term mindset helpful build triple thermal pane combine close marathon runner project last cavity air integrate sunscreen reduce glare seven year project initiation inauguration help insulate interior heat cold final phase tough stretch quicken pace meet second pillar sustainable source deadline long hour work energy building heat waste heat generate lead light efficient hard colleague resolve problem manufacture site basel ground fluorescent light create unique design element finish project time budget roche environment community environment community roche limit air emission indianapolis branchburg switch refrigeration fire suppression supplier sustainable source wind power scope achieve reduction energy save tonne increase energy efficiency reduce cdp carbon disclosure project achievement halogenate hydrocarbon tonne roche identify global leader action strategy response climate change award position global inventory climate list cdp international notfor business production continue majority ghg emission originate consume profit organisation drive sustainable economy grow committed maintain low transformation use energy goal furthermore roche obtain disclosure score global inventory include chugai genentech ventana level air emission achieve date improve energy efficiency apply ghg identify leader emission strategy prescribe continuous improvement emission reduction scope initiative reduce ghg emission dach region germany austria switzerland manufacturing site include flue scope ghgs employee tenyear period reduce use halogenate substance quality climate changerelate information gas scrubber reduce nitrogen oxides sulphur favour use carbon offset purchasing refrigeration andor fire suppression successive year roche dioxide incineration freeze socalle certificate compensate remain atmosphere long period award position dach climate disclosure process reduce release volatile organic emission alternative drive effort time plan reduce halogenated substance leadership index compound voc reduce energy reduce emission ghg baseline roche legacy site use emission air voc decrease emission originate facility exclude acquisition include genentech disclosure score confirm understand nitrogen oxides scope amount tonne scope ventana work business issue relate climate change particulate remain unchanged sulphur dioxide ghg emission total timeline great effort manage incorporate climaterelate risk opportunity increase mainly improved reading combine scope ghg emission cut achieve reduction set core business roche performance score ventana site emission air site reduction achieve new goal reduce halogenate substance signal measure verifying manage low level mean new process implement energysave measure reduce roche legacy site year carbon footprint activity time sampling fuel use heat cool operate continue examine alternative work result fluctuation see past year site major contributor success equivalent emission metric tonne scope halogenate hydrocarbon scope total scope scope total employee scope business flight energyintensive utility datum collect group compress air liquid nitrogen roche environment community environment community roche manage limited water resource reduce recycle purify wastewater release water treatment plant meet requirement release river lake pharmaceutical industry globally poor deliver onsite treatment plant quality water result high cost purification treat biologically anaerobic condition pretreate wastewater reduce great risk product contamination produce biogas mean methane content high seek minimise chemical biotech pharmaceutical diagnostic desulphurise burn combined contamination water discharge minimise contamination manufacturing process involve water reagent heat power unit plant produce electricity reduce discharge toxic poorly solvent cleaning cool agent use water heat annually generate electricity value biodegradable substance heavy metal water energy carrier heating refrigeration eur heat byproduct reduce generation wastewater installation heat building energy worth eur treating pretreate wastewater ozone year additionally external combustion case non poorlydegradable water goal reduce consumption transportation aqueous solvent mixture avoid contaminant relate issue affect reputation investor employee weight accord save eur year generation increasingly show interest water policy water stress respective region roche site electricity source fossil fuel reduce water usage remain relatively unchanged performance work implement programme emission importantly process past year withdraw reduce water consumption recycle reuse produce energy need run plant million water different source water usage discharge water example roche basel invest change water treatment energy user approximately consume technology save water money chemical energy producer treat wastewater meet constituent product vaporise reaction require cool perform high respective requirement discharge refrigeration air conditioning plant water withdraw temperature conventional laboratory condenser local river support global effort promote irrigation discharge salt brackish million cubic metre attach directly cold water tap consume water protection aim reduce total wastewater water lose fresh water approximately water consume litre water minute average toxicity select production plant water discharge include million cubic metre price chf cost water baseline chemically contaminate water send final wastewater discharge synthesis come chf condenser destination treatment plant increase treatment plant year air coolant instead multiple approximately half water draw increase site report million cubic metre reaction run time add cool circuit water chemically parameter addition heavy metal organic matter considerable saving new technology contaminate analyse directly discharge discharged operation waterway discharge waterway reduce risk water supply furthermore discharge wastewater treatment tonne disconnected spring leak pollutant comply fully relevant regulation demand fresh water increase heavy metal discharge quickly flood laboratory include pretreatment requirement record total effective water management crucial avoid water waterway organic carbon toc discharge water follow scarcity procedure place ensure treatment kilogramme roche penzberg earn award process wastewater treatment plant efficient water use business continuity water innovation environmental responsibility approximately measure toc reduction selfpowere highefficiency wastewater treatment elimination rate wastewater treatment plant plant wastewater site collect roche environment community environment community roche waste management waste tonne send nonrecyclable waste approximately site total wastetoenergy plant ensure value recover minimise waste maximising recycle general waste site waste send landfill generate chemical waste roche act concern impact generate pharmaceutical environment consider construction waste entire lifecycle product goal roche strive implement follow strategy year plan remediation safeguard ecosystem secondly activitiesavoid reduce reuse recycle thermally kesslergrube landfill grenzach begin louisville distribution facility protect business potential longterm destroy permit landfilling resort september construction genentech site achieve zero waste landfill financial reputational risk inert material slag necessary infrastructure include bypass road year site disposed increase incineration ash depend availability temporary shiplande dock excavation volume coldchain pallet shipping container mabtherarituxan avastin herceptin lucentis suitable local wastetreatment plant dispose contaminate soil start contain mixture cardboard styrofoam water monoclonal antibodie nonhazardous general waste authorise landfills careful planning stepbystep approach roche fill cold pack wood pallet address generate chf billion sale roche accept landfilling chemical waste ensure safe efficient execution complex challenge site implement comprehensive low excretion rate judge hazardous material remediation programme keep emission recycling process divert cardboard wood plastic respective authority present significant risk minimum close dialogue maintain styrofoam previously take sewage work surface water set new goal general chemical local resident landfill volume facility deliver term benign nature constitute environment waste reduction shipping container recycler approximately ally sustainable compound reduce general waste employee roche produce relatively low volume chemical shipping container vocational programme fiveyear period generate small quantity chemical employ adult special need disassemble encourage green chemistry set reduce landfilling organic chemical waste continue reduce recycle material technical working group presence fiveyear period low volume waste production biotech europe group dedicate develop accept responsibility waste generate product increase chemicalbased production currently programme receive approximately implement good practice promote green operation include previously deposit decline roche generate tonne usd activity financial chemistry roche genentech site landfill chemical waste general waste incinerate value recyclable material reinveste furthermore roche environmental awareness landfille increase largely provide employment people disability chemical technology react award give continue remediation demolition cleanup activity nutley site louisville work vocational programme annually employee demonstrate programme activity cleanup soil tonne generate enhance work stream process number environmentally friendly approach site nutley complete yearend construction demolition waste comprise shipping container maximise recycling chemical synthesis cleanup groundwater underway tonne site south san site waste streams louisville site year complete plan div francisco grenzach main contributor property retain responsibility environmental cleanup post divestment roche remediation project nutley clear commitment longterm value site community roche environment community environment community roche employee raise fund partner support local community record participation employee site raise child world well life approximately chf million majority philanthropic engagement fund provide child malawi education school supply water sanitation roche commitment malawi span year roche work school create wellbeing help support child programme offer education topic hiv education remain fund collect aids prevention healthy lifestyle management roche commit sustainable philanthropic year widespread flooding pakistan children walk support different children personal finance skill activity span community involvement roche help open new primary school programme local community humanitarian project science education art jacobabad city particularly hardhit roche operate world important initiative genentech culture goal establish longterm roche helped build equip operate school foundation provide support eastside partnership focus project add collaboration citizen foundation roche support initiative college preparatory school palo alto california last value society local nonprofit organisation focus improve provide accessible highquality holistic education goal quality education available education student disenfranchise young adult programme child live difficult neighbourhood respond natural disaster enrol girl school aim innovative maharishi institute south year row eastside graduate follow natural disaster roche work local increase support education equality africa provide free tertiary education young go fouryear college partner provide immediate support essential country people experience particular hardship donation medicine longterm support help community rebuild important initiative report year disaster relief follow flood malawi nepal strike devastating earthquake january accord united nations kill injure thousand displace million children fund people affect response roche donate vial roche financial donation support disaster rocephin antibiotic treat wide range relief effort include distribution mosquito roche financial donation support disaster relief effort malawi include distribution mosquito net infectious disease form net protect displaced people malaria tuberculosis meningitis roche india disease local stock provide immediate help additionally chugai donate jpy million japan platform support education emergency aid organisation roche longstanding philanthropic commitment malawi southeast africa support education programme hivaid natural disaster roche react orphan child year employee involve raise money participate immediate need provide roche children walk sustainable help wwwrochecomphilanthropy wwwrochecomchildrenswalk roche environment community environment community roche generation scientist help student unleash potential genentech employee volunteer serve coach mentors weekly tutoring programme researchbase healthcare company science communicate result scientific report technology core poster english final round support multiple programme promote bestperforming class invite special event helix cup annual science competition helix cup genentech futurelab interest discipline young people roche basel innovative live presentation focus realworld challenge associate programme multiyear partnership ssfusd year time seek inform result experience class deliver healthcare medicine programme involve major commitment include educational career opportunity creative imaginative convincing presentation need challenge give student opportunity construction usd million standalone area select expert jury award science deepen understand key concept biotech teaching facility ssf high school week abroad science engage format help campus slate break ground include build foundation science technology develop skill creativity problemsolve creation stateapprove high school biotech provide realworld science skill enable class participate programme teamwork curriculum college scholarship promise continued education career biotech hope travel basel display student pursue degree science technology help grow generation innovator science scientific knowledge enthusiasm creativity student participate helix cup engineering math field helix cup project conduct winner class kantonsschule zug receive designing solution potential barrier switzerland respectively lead weeklong science trip visit deliver medicine remote area keep addition serve coach employee act example effort support young scientist roche site creativity workshop medicine cool delivery round mentor weekly tutoring programme local science student attend lecture london competitive challenge team elementary school student advisor ssfusd experiment science school hygiene tropical medicine school come genentech ssf site compete science teacher donate hard work establish science set royal society chemistry visit fourth final challenge determine project improve playground facility hopeful discoverer switzerland open renowne science museum sponsor roche win team ssf school secondary class project culminate run simplyscience foundation science biannual competition engage young people initiative scienceindustrie genentech employee involve fun genentech employee science teamwork fun programme foster represent swiss business association volunteer coach support student student interest biology science identify chemical pharmaceutical biotech industry competition encourage directing team volunteer futurelab class great dedication commitment explain genentech serve field solve healthcare challenge positive role model share inspire programme year genentech long history support science career journey competition challenge broad range ability education south san francisco ssf student explore experiment theorie main company site locate genentech showcase scientific communication introduce helix cup handson competition skill traditional innovative way science design bring science alive student consist phase phase south san francisco unify school district goal conduct biological ssfusd biochemical experiment laboratory wwwrochecomscienceeducation wwwgenecomgoodgivingfuturelab roche corporate governance corporate governance roche cor porate gove nance roches corporate governance aim safeguard sustainable interest company year unne roche rank sustainable healthcare company dow jones sustainability indice roche corporate governance corporate governance roche annual general meeting annual general meeting principle board director roche commit serve stakeholder governance requirement particular board director board committee basis successful implementation applicable law swiss stock exchange swiss board committee presidium nomination committee commitment corporate governance principle exchange directive swiss code well accordingly focus business activity practice corporate governance promulgate remuneration committee sustainable value creation innovation swiss business federation economiesuisse audit committee prescribe management culture conform company internal governance framework recognise standard good corporate governance particularly article incorporation bylaw corporate governance sustainability committee policy transparent communication embody principle need ensure company business manage supervise corporate executive committee strong board director represent manner consistent good corporate governance corporate executive interest shareholder stakeholder include necessary check balance coo coo general committee ceo cfo highly skilled manager act integrity pharma diagnostic counsel extremely important print annual report contain select link roche website wwwrochecom reader consecutive year roche provide snapshot company enlarge corporate executive committee enlarge corporate recognise dow jones sustainability indices report date direct source gre pre partnering communication group leader sustainability consult time uptodate executive committee pharmaceutical biotechnology life science information corporate governance roche chugai industry sustainability core business annual report cover single financial practice award reflect commitment year end december website contain run business way ethical responsible information permanent nature create longterm value stakeholder late roche news company article incorporation bylaw curricula vitae corporate governance report set member board director corporate structure process rule roche take executive committee publish website basis wellfunctione corporate governance roche complie relevant corporate detail refer follow report wwwrochecomgovernance roche corporate governance corporate governance roche board director board director annual general meeting agm march forthcoming agm board director board committee roche holding ltd march shareholders board director nominate chairman board committees presidium nomination committee reelect christoph franz chairman remain member board director board director reelection announce deanne remuneration committee julius member board director audit committee furthermore agm reelect andr hoffmann decide stand reelection pius baschera john bell paul bulcke deanne julius announce december addition beatrice corporate governance sustainability committee andreas oeri severin schwan peter voser weder mauro member board beatrice weder mauro elect bernard poussot decide stand reelection richard lifton new members board board nominate mrs julie brown mrs claudia director term year provide sssmuth dyckerhoff election new member article incorporation board director agm composition year birth elect addition agm elect christoph franz board director nominate board directors christoph franz chairman andr hoffmann peter voser bernard poussot christoph franz andr hoffmann peter voser andr hoffmann vicechairman members remuneration committee bernard poussot reelection richard representative shareholder group lifton election member remuneration pool voting right organising meeting immediately follow committee agm andreas oeri agm board director determine representative shareholder group structure composition remain board director nominate bdo pool voting right committee show page independent proxy period prof pius baschera board director corporate conclusion ordinary annual prof sir john irving bell executive committee general meeting shareholder election paul bulcke agm dame deanne julius prof richard lifton bernard poussot severin schwan peter voser prof beatrice weder mauro secretary gottlieb keller board director honorary chairman fritz gerber board director corporate governance sustainability committee audit committee remuneration committee presidiumnomination committee nonexecutive director executive director committee chairperson roche corporate governance corporate governance roche corporate executive committee corporate executive committee corporate executive coo coo general committee ceo cfo pharma diagnostic counsel membership corporate executive committee remain unchanged enlarge corporate executive committee enlarge corporate information member corporate gred pre partnering communication executive committee executive committee enlarge corporate chugai executive committee list page board director corporate executive committee composition year birth position corporate executive severin schwan ceo roche group committee daniel oday coo division roche pharmaceutical roland diggelmann coo division roche diagnostic alan hippe chief financial officer silvia ayyoubi head group human resources gottlieb keller general counsel enlarge corporate osamu nagayama chairman ceo chugai executive committee michael varney head genentech research early development gre prof john reed head roche pharma research early development pre stephan feldhaus head group communications sophie kornowskibonnet head roche partnering secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler reporting year roche holding ltd kpmg auditor charge john morris ian starkey chief compliance officer urs jaisli roche corporate governance corporate governance roche roche pharma incl genentech pharma chugai professional diagnostic molecular diagnostic diagnostic group structure shareholder tissue diagnostic diabete care roche operate business organise note financial statement roche composition division pharmaceutical diagnostic hold ltd significant shareholder pharmaceutical division comprise business addition significant shareholder publish segment roche pharmaceutical chugai relevant webpage disclosure office genentech segment exchange regulation wwwsixexchangeregulationcom capital structure integrate roche pharmaceutical diagnostic enhomepublicationssignificantshareholdershtml division consist follow business area diabetes care molecular diagnostic professional andr hoffmann vicechairman board diagnostic tissue diagnostic director chairman remuneration information roche capital structure provide include provision protect interest committee andreas oeri member board finance report note financial statement ofne holder describe article business activity carry group director chairman board corporate roche hold ltd additional detail incorporation roche holding ltd subsidiary associate company detail governance sustainability committee serve contain article incorporation information roche holding ltd significant respective capacity board roche holding ltd information debt instrument subsidiary associate company include committee representative shareholder issue outstanding bond provide company list information domicile share group pool voting right receive movement recognise amount finance report note roche group capital equity interest list finance remuneration set forth remuneration report financial year detailed finance consolidate financial statement debt report note roche group consolidated finance report note report note financial statement roche financial statement subsidiary associate roche group consolidate financial statement hold ltd information employee stock option provide related party exception finance report note roche group jrg duschmal work postdoc roche company share capital chf consolidated financial statement equity major shareholder list finance report relationship exist shareholder divide fully pay bearer share compensation plan include detailed note roche group consolidate pool voting right nominal value chf information stocksettle stock appreciation financial statement equity attributable roche restriction exercise vote right right ssar plan roche restrict stock shareholder relate party page crossshareholding share deposit share vote unit plan roche performance share plan restriction roche connect roche option plan authorise conditional capital roche issue option apart employee stock option describe finance report addition nonvoting equity security note roche group consolidated financial ne issue bearer form statement equity compensation plan form share capital confer voting option issue connection debt instrument right ne confer right share participate available earning option award employee liquidation proceed follow repayment share debt instrument issue capital roche nes right pertain thereto effect roche share capital wwwrochecomarticleofincorporation roche corporate governance corporate governance roche board director board director board committees board committee presidium nomination committee board director corporate remuneration committee audit committee executive committee corporate governance sustainability committee information member board director exception severin schwan corporate executive member corporate executive member board director office end corporate executive committee committee committee list page member member roche corporate board director age limit restriction executive committee serve executive capacity term office curriculum vitae current group subsidiary financial member year year preceede current reporting period body information include information lack exist business connection describe committee report operate financial risk risk year election board member group subsidiary independent authority responsibility define detail management system additional position membership activity bylaw board director roche group establish risk management available continuously update internet principle governance principle process cover entire company system delegation competence reservation power committee chair independent place identify manage type risk rule pursuant article para point vegv management group company director potentially affect business include economic number permit activity board executive body company include economic environmental social impact risk director corporate executive committee environmental social topic principle accord bylaw board director opportunity contain stakeholder input member outline article internal organisation board board meeting convene board director high governance incorporation roche holding ltd director division authority responsibility chairman present request member body involve roche risk management policy set board management remit roche board meet year assess approach accompany responsibility annual general meeting elect board committee information control chairmans performance meeting pharmaceutical diagnostic division member board director chairman mechanism available board dealing attend chairman chair global function conduct formal risk assessment board director member corporate management govern bylaw vicechairman process year develop remuneration committee annual basis risk plan material risk election nominee vote separately board director roche holding ltd management information system mis monitor deviation review regular article incorporation roche organise ensure group conduct board director inform performance dialogue consolidate group hold ltd minutes annual business responsibly focus longterm important issue sale performance etc monthly risk report include target risk profile discuss general meeting roche holding ltd hold value creation end roche board basis board access electronic information corporate executive committee approve march delegate certain responsibility committee platform provide timely information group business plan material composition chairperson december board director board committee risk review board yearly basis system control set forth process subject regular review finding present audit committee wwwrochecomboardofdirector wwwrochecomexecutivecommittee board director establish system board effectiveness risk management wwwrochecomarticleofincorporation controls continuously monitor process monitor group risk advisory wwwrochecomannualgeneralmeeting audit committee corporate governance team overall process regularly review wwwrochecomarticleofincorporation sustainability committee board external auditor wwwrochecomcommittee director consist follow element detail risk management include risk wwwrochecomarticleofincorporation factor risk management policy risk roche corporate governance corporate governance roche management compliance website efficiency process control action plan october october board director regularly conduct financial risk management specifically describe implement necessary change enhancement blackout period change chairman assessment selfassessmentassessment party finance report develop businessauditee board director circumstance warrant electronical survey personal interview system internal control financial reporting track completion performance independent assessment page finance report statutory auditor board director meet meeting party conduct internal audit chief compliance officer compliance officer generally hour length include group audit report general counsel subsidiary fullday meeting addition day visit member corporate executive committee direct access give regular briefing audit safety health environmental protection major subsidiary board committee meet maximum ordinary notice period month committee corporate governance department follow changeofcontrol clause sustainability committee ongoing activity corporate sustainability committee presidium board directorsnomination employment contract audit report chief audit risk advisory science ethic advisory group seag committee meeting approx hour executive attend audit committee partly issue relate genetic genetic engineering include telephone conference management contract fall corporate governance sustainability remuneration committee meeting approx scope subsection annex directive committee meeting external auditor member corporate executive committee hour information relate corporate governance group audit independent appraisal function invite attend meeting board audit committee meeting approx hour evaluate review group activity director report person agenda service management annual audit plan item concern situation warrant corporate governance sustainability yearly define focus area emerge member enlarge corporate executive committee meeting approx hour market thirdparty management validate committee invite attend board senior management present audit committee invite chairman board committee roche group commit corporate executive committee member deliver board board committee attendance maintain high standard internal control report committee meeting elect worldwide operation management commission independent expert report corporate presidium governance responsible assess business risk service consultant nomination remuneration audit sustainability aspect operation implement board committee committee committee committee effective efficient process control whilst year blackout period impose number meeting ensure compliance internal external senior employee prohibit franz rule regulation trading company stock follow blackout hoffmann conduct operational audits group audit period effect baschera determine management response risk december january bell surround business process system april april bulcke evaluate appropriateness completeness june july julius lifton poussot wwwrochecomriskmanagementandcompliance schwan additional information provide finance report note roche group consolidate financial statement risk management oeri voser wwwrochecomenvironment weder mauro wwwrochecomsustainability member committee wwwrochecomethicalconflict invite guest board committee meeting figure indicate actual length meeting include director extensive premeete preparation postmeete remuneration committee member recuse deliberation decision matter affect interest followup activity roche corporate governance corporate governance roche remuneration shareholding loan participatory right shareholder detail remuneration shareholding rule aol participatory right shareholder article incorporation loan content method determine content board cec define roche article incorporation shareholder represent share nominal compensation shareholding programme rule principle roche share issue bearer value chf million request basic principle element compensation applicable performance restriction admission annual general placement item agenda annual shareholding programme serve related pay meeting exception share general meeting later member board director corporate rule principle deposit specify period date day date meeting executive committee description allocation equity securities meeting admittance card issue authority procedure determine convertible right option shareholder provide rule issue instruction set forth separate remuneration report additional payment article incorporation shareholder elect independent proxy rule electronic page finance report note member executive represent party annual participation agm lay roche group consolidated financial committee appoint general meeting correspond invitation agm statement equity attributable roche shareholder vote pay general regulate article incorporation relate party page list meeting shareholder article incorporation contain restriction note financial statement roche holding rule loan credit facility exercise voting right quorum ltd board executive shareholding postemployment benefit requirement stipulate conformity rule vote pay swiss code obligation follow rule remuneration shareholding agm loan board director board corporate executive committee cec set forth article incorporation aoi andreas oeri chairman corporate governance sustainability committee wwwrochecomarticleofincorporation roche corporate governance corporate governance roche change control defensive measure legal requirement company formal policy governing attestation service comfort letter consent engagement statutory auditor nonaudit consultation service policy prohibit certain service provide permit certain service article incorporation contain provision terminate event acquisition tax service include service respect limit agree audit committee mandatory bid rule swiss law apply vest period restriction preexist award compliance tax return tax advice potential nonaudit service engagement review remove option service relate audit tax policy authority proceed changeofcontrol clause exercise immediately give component remuneration base roche ne service include advice relate process improvement regulation training relationship statutory auditor relationship independent proxy annual general meeting roche holding ltd kpmg receive follow remuneration march shareholder vote appoint service statutory auditor roche holding ltd recent year bdo serve independent rule issue instruction kpmg kpmg statutory auditor base auditor roche company proxy annual general meeting march independent proxy rule electronic exist legal requirement swiss code include chugai shareholder elect bdo independent participation agm lay obligation article concern maximum proxy period conclusion correspond invitation agm term office seven year auditor charge ordinary annual general meeting regulate article incorporation ian starkey replace predecessor john morris millions chf shareholders bdo pay services auditorincharge start business year auditing service accord expenditure totalling chf information long auditor auditorin auditrelated services chf charge serve capacity provide account statutory auditor participate assurance audit committee meeting prepare write tax service oral report result audits audit service committee oversee assess auditor total make recommendation board information authority responsibilitie audit statutory auditor elect year committee article bylaw annual general meeting statutory auditor participate meeting audit committee auditing service provide legally require report statutory auditor consolidate auditrelated service include assurance financial statement financial statement accounting service provide auditor find page respectively necessarily provide statutory auditor year finance report service include audits pension fund employee benefit plan internal control review wwwrochecomarticleofincorporation roche corporate governance corporate governance roche information policy chief compliance officer compliance officer network provide article incorporation relevant information document include corporate notice publish swiss official medium release investor update presentation gazette commerce daily newspaper analyst investor conference available chief compliance officer compliance group code conduct reference document designate board director basler zeitung internet publication order officer network commit ensure furthermore serve platform idea finanz und wirtschaft lagefi temps neue email fax telephone roche group code conduct consistently suggestion concern document zrcher zeitung baselwebmasterrochecom comply roche group tel serve contact person shareholder employee addition roche establish business ethic roche report halfyear fullyear result fax customer supplier general public issue incident report beir system enable business report publish print andor online relate implementation compliance chief compliance officer capture track format medium event addition detailed contact address investor relation code employee party monitor allege violation initial report thirdquarter sale figure publish hoffmannla roche ltd investor relation aware violation roche group code local compliance officer resolution year april october current list group finance basel switzerland conduct bring attention business ethic incident record system publication date available english tel manager supervisor local compliance local management receive specific german internet fax officer report chief compliance officer concrete information allege violation urs jaisli direct phone number roche group code conduct certain pre additional information include detail specific email ursjaislirochecom disclosure define category corporate governance contact person available internet treat confidentially addition end sustainability committee audit committee employee anonymously report irregularity board director inform substantial complaint mother tongue speakup violation management corrective action line start december new compliance tool group level socalle roche group code chief compliance officer report general conduct help advice line introduce counsel submit regular report strives provide guidance case question corporate governance sustainability committee uncertaintie interpretation roche audit committee board director nonapplicabilitynegative disclosure wwwrochecomarticleofincorporation wwwrochecommedia wwwrochecominvestor wwwrochecominvestorscontact expressly note information contain provide swiss exchange corporate wwwrochecomcodeofconduct mention nonapplicable governance directive commentary thereto wwwrochecomriskmanagementandcompliance omission construe negative declaration roche remuneration report remuneration report roche remuneration report roche commit compensation system balance performanceoriente align interest employee owner company employee satisfy benefit accord global employee opinion survey roche remuneration report remuneration report roche principle roche success depend substantially expertise compensation package competitive motivation performance employee structure individual component conviction form basis compensation policy regularly benchmarke swiss european international criterion remuneration guideline roche aim remunerate employee fairly underlying principle subject transparently line market condition regular outside comparison toenable participate appropriately company success pursue goal provide compensation policy factor competitive performancebase compensation safeguard roche future success wwwrochecomrewards key element strive balanced mix fix variable corporate culture offer employee condition compensation component gear employee good possible contribution position management responsibility share corporate goal improve healthcare patient include sound value system variable component intend create base integrity courage passion additional financial incentive achieve corporate wwwrochecomlivingourvalue time goal innovation consistently high decentralise management approach play level increase value company major role wide scope individual decision create stakeholder group make respectful interaction openness diversity time order allow employee manager widerange training development opportunity participate company business success attractive working environment employee adequate compensation measure key motivation loyalty organisation solely incentive form annual bonus payment base term compensation longterm sharebase programme roche commit fair balanced performance global company like roche marketcompetitive base compensation policy link employee remuneration play key role performance interest stakeholder group base transparent compensation structure ensure roche remuneration report remuneration report roche remuneration decision process consulting firm pricewaterhousecooper pwc assist meet approval implement ordinance roche perform market comparison excessive compensation list corporation advise remuneration committee information verordnung gegen bermssige vergtungen bei approval framework remuneration committee remit power brsenkotierten aktiengesellschaften vegv procedure make remuneration decision general meeting shall vote annually bind find bylaw roche board director effect approval remuneration overview recommendation remuneration article incorporation board director resolve board year remuneration committee roche committee outline section principle director corporate executive committee board director meets twice decide govern specific remuneration component detail remuneration board member member remuneration committee track market datum group corporate executive committee salary lead global pharmaceutical total aggregate amount base term performance share plan psp award company major swiss company decision submit general decide annually board director act report finding board external remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman committee cec peer set ceo abb abbott laboratories base payremuneration actelion abbvie bonus credit suisse amgen stocksettle stock remuneration committee lafargeholcim astellas appreciation right annual general nestl astrazeneca restrict stock unit meet nobel biocare bayer roche performance share plan board director sonova bristolmyers squibb recommendation straumann eli lilly remuneration committee swiss glaxosmithkline decision pension remuneration committee ubs johnson johnson zurich insurance merck novartis peer set pfizer sanofi takeda peer set abbott laboratories abbvie amgen astella astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline market comparison company salary assessment johnson johnson merck novartis pfizer sanofi takeda change composition peer set compare pharma peer set abb actelion credit suisse lafargeholcim nestl nobel biocare sonova straumann swis ubs zurich insurance major swiss company wwwrochecomarticleofincorporation wwwrochecomarticleofincorporation roche remuneration report remuneration report roche procedure submit total board retrospective approval approval total remuneration annual general financial year financial year executive remuneration shareholder approval total aggregate bonus amount corporate meeting annual general meeting executive committee chairman board retrospective year annual general meeting agm director financial year end shareholder approve total remuneration submit retrospectively ordinary agm board director corporate executive separate bind approval chairman bod committee decide board director bonus financial year total bonus remuneration committee board director prospective approval respectively board executive aggregate remuneration corporate executive committee cec cec submit prospectively agm separate bonus financial year total bonus accord approval agm roche bind approval period commit obtain separate bind ordinary agms prospective shareholder approval total remuneration pay board director corporate executive committee follow board director bod include bod aggregate total remuneration agm agm base payremuneration base payremuneration corporate executive committee cec include ceo aggregate total remuneration agm agm cec base pay base pay ssar stocksettle stock appreciation right ssar psp performance share plan psp indirect benefit indirect benefit andr hoffmann chairman remuneration committee agm agm agm roche remuneration report remuneration report roche variable sti bonus base salary lti indirect benefit employer contribution stocksettle stock pension insurance contribution appreciation right roche ahvivalv performance share plan roche connect remuneration component remuneration restrict stock unit tax consulting service component expense allowance overview remuneration element align interest roche employee remuneration member board shareholder children school cost director corporate executive committee foreign tax obligation compose follow element lti remuneration component intend fix sustainably homogenously longterm orient fix base salary complement annual align management interest shareholder variable bonus shortterm incentive sti holder nonvoting equity security perennial variable remuneration element participate manager additional incentive ssar psp rsus longterm incentive lti achieve continued value growth form long term total shareholder return create value remuneration component link roche investor management benefit base pay fix qualitative individual functional performance employee performance company financial add longterm value create investor base pay cash payment determine objective competitive reason roche performance commercial success management penalise receive position base salary market datum lead disclose individual performance objective global pharmaceutical company footnote member corporate executive committee major swiss company footnote reflect individual ability experience december end report year performance time pay adjustment likewise january follow report year remuneration link individual performance account committee decide bonus amount prevail market condition company payable chairman board member overall financial situation corporate executive committee respect composition remuneration board director corporate executive committee current reporting year base performance remuneration committee make review aforementioned objective annual remuneration element description bod ceo cec final decision individual base pay pay time remuneration committee decide base pay monthly payment uarterly chairman board director member form bonus award cash payment remuneration payment corporate executive committee andor block nonvoting equity security andor bonus annual payment year year cash remuneration member board block share block share block share pension etc bonus variable stocksettle stock appreciation right perennial bonus annually award individual variable remuneration element contribution value creation business year stocksettle stock appreciation right ssar stocksettle stock mean incentive strive outstanding plan introduce establish uniform appreciation right result create new business opportunity system remuneration roche ssar ssar bonus amount link group divisional entitle holder benefit financially increase performance share year profit sale growth operate profit capital value roche nonvoting equity security plan psp block share charge opac earning share nonvoting grant date exercise date restrict stock replace replace equity security ne growth product development ssar grant cec member vest unit rsus ssarspsp ssarspsp pipeline achievement measurable year exercise roche remuneration report remuneration report roche seven year grant date unexercised ssar rsus remuneration component continue psp historical performance indirect benefit lapse compensation fair value authortise roche employee award originally target ne show ceo ssar calculate grant date chairman respectively member corporate trinomial model american option detail performance share plan psp variable executive committee additionally receive indirect member corporate executive committee benefit payment pension fund mgb stiftung member senior management currently der hoffmannla roche mitarbeiter ssar awards allocate individually individual worldwide participate gewinnbeteiligung als ergnzung der beruflichen remuneration committee discretion performance share plan psp establish vorsorge employee profitshare foundation period year base supplement occupational pension benefit restrict stock unit variable threeyear comparison total shareholder insurance roche connect payment restrict stock unit rsusright receive non return tsr peer company footnote foreign tax obligation tax consulting service vote equity security andor share annual expense allowance show year vest period plus value adjustment respective year psp consist individual member corporate executive equivalent sum dividend pay overlap performance cycle new cycle committee receive payment school cost vest period attributable number start beginning year cycle child nonvoting equity security individual finishing end year award grantedwere introduce new remuneration component partially replace overlap ssar rsu award allocate individually performance cycle psp psp weight fixedvariable remuneration component target percentage total remuneration remuneration committee discretion psp psp close vest recipient year december result nonvoting equity security remain chairman block year vest psp cycle target ne block period interest rsu recipient award psp december board director shall align company longterm success target ne award commitment employee company corporate executive shall increase plan key performance metric award committee include ceo total shareholder return tsr calculate value ssar awards reduce threemonth move average rate start balance award form rsus end performance cycle fix variable payment performance share plan rsus remuneration component determine board director annual corporate executive committee replace basis act recommendation award correspond psp remuneration committee variable longterm incentive programme corporate executive committee comprise psp award ssar roche remuneration report remuneration report roche ratio variable remuneration component relative fix base pay corporate executive change respect remuneration comprise psp ssar award committee component structure lti simplify calculation psp value comparison competitor company ratio variable remuneration component bonus ssarsrsus psp relative value fix base pay correspond reporting year newly base performance reflect share price fair value grant bearer share price average total shareholder return shall incorporate sti lti month october december deeply corporate executive criterion bonus ssarsrsus psp prior start performance cycle committee remuneration individual target value ssar calculate target roche security rsus entire psp year cycle start psp award remuneration minimum distribution year instead component reserve corporate maximum calculation cycle correspond executive committee enlarge corporate performance criterion group objective group value development value development determine distribution report year cycle disclose executive committee longterm divisional business determine performance performance start target remain cycle psp base incentive programme previous psp performance individual plus value adjustment psp cycle plus actual value psp vest year participant comprise ssar rsus objective consider profit dividend ne value adjustment dividend award sale growth opac operating grant nesbearer share rsus corporate executive profit capital charge grant committee replace award additional detail refer follow earning share ne group performance tsr psp future longterm incentive section remuneration report growth product development relation tsr performance programme corporate executive committee pipeline peer set tsr definition split group objective individual objective assess consideration performance competitor macroeconomic development base annual base pay measure january year cycle finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding roche remuneration report remuneration report roche remuneration board director resolution approval remuneration chairman board director member board director decide remuneration committee discretion take account market comparison remuneration form cash payment annually track market datum director pay lead global pharmaceutical company footnote major swiss company footnote assist consultancy pwc previous year board director separately submit total aggregate bonus chairman board directors general meeting financial year retrospectively bind approval maximum amount total aggregate remuneration board director period ordinary general meeting ordinary general meeting table previous year general meeting prospectively bind approval remuneration member board director member board director receive remuneration additional compensation form quarterly fix cash payment show list member position committee membership chairmanship detidua remuneration member board director table board activity roche pay legally require employer contribution total chf chf swiss social security programme provide retirement disability unemployment benefit ahvivalv member board director legally require contribution separately state chairman board director basic remuneration board director exclude chairman remain unchanged remuneration member board director remain unchanged exception chairman board director bonus form block share severin schwan executive member board member board director award share nonvoting equity security ssar rsus loan credit grant member board director capacity member international advisory council iac chugai pharmaceutical ltd andr hoffmann receive honoraria amount total usd chf detidua remuneration member board director chf additional compensation additional special basic remuneration committee memberschair compensation total remuneration franz chairman total remuneration pay chairman board director hoffmann vicechairman baschera bell bulcke julius lifton poussot oeri schwan high total remuneration pay severin schwan member corporate executive committee remuneration receive primary function ceo reflect total remuneration corporate executive committee voser weder mauro total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december additionally employer contribution ahvivalv totalling chf include chairman pay form compensationroche remuneration report remuneration report roche remuneration member board director chf additional compensation additional basic remuneration committee memberschair special compensation total remuneration franz chairman total remuneration pay chairman board director hoffmann vicechairman baschera bell bulcke julius lifton poussot oeri schwan high total remuneration pay severin schwan member corporate executive committee remuneration receive primary function ceo reflect total remuneration corporate executive committee voser weder mauro franz humer retire burn retire levinson retire total prorate remuneration serve chairman board period january march amounting chf bonus award chf form share block year calculation number share base share price date transfer april calculation value consideration reduction value block period year reduce market value employer contribution employee stock purchase plan roche connect prorate period january march amounting chf payment tax consulting service chf plus prorate remuneration pension fundsmgb stiftung der hoffmannla roche mitarbeiter gewinnbeteiligung employee profitshare foundation supplement occupational pension benefit chf additionally employer contribution ahvivalv chf chf pay form compensation franz humer receive advisory capacity presidium plan year chf total pay franz humer receive honoraria amount total usd chf serve member international advisory council iac member board director chugai pharmaceutical ltd start april prorate remuneration period january march prorate remuneration period january september footnote activity member board additionally employer contribution ahvivalv totalling chf include chairman pay form compensation detidua total remuneration pay chairman board director chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowance total prorate remuneration member board director period march december chairman board director period march december form share block year calculation number share base share price date transfer april respectively approval agm agm calculation value consideration reduction value block period year reduced market value approve agm submit shareholder approval agm include employer contribution social security beneficial part detidua total remuneration pay chairman form bearer share block year payable board director april shareholder bind vote chairman christoph franz receive total ordinary annual general meeting agm remuneration show remuneration committee bonus proposal adopt chairman total remuneration contain late respect financial year total remuneration board director total remuneration pay board member board director member directors international advisory council iac chugai calendar year members pharmaceutical ltd addition chf board director receive remuneration employer contribution pay ahvivalv include bonus totalling chf chf tax consulting service pay chf exclude additional employer time contribution pay ahvivalv totalling chf chf member board director william form compensation burn receive honoraria amount total usd chf capacity remuneration pay member member international advisory council board director iac chugai pharmaceutical ltd member board director franz humer receive honoraria amount additional remuneration pay total usd chf serve mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit additionally employer contribution ahvivalv chf chf pay form compensation detidua detiduaroche remuneration report remuneration report roche board remuneration subject approval table total remuneration pay chairman submission board total aggregate severin schwan remuneration show annual general meeting board director board future remuneration bind shareholder vote receive function ceo member director submit remuneration committee board director propose corporate executive committee include submission chairman total aggregate bonus proposal adopt late chairman ordinary agm approve board remuneration totalling corporate executive committee bonus bind vote annual general board christoph franz respect chf exclude legally total remuneration meeting financial year payable april exclude legally require employer contribution ahvivalv remuneration chairman board require employer contribution ahvivalv exclude bonus period end director include bonus award chf shareholder bind vote ordinary ordinary agm form share block year show annual general meeting agm prospective approval board total aggregate future remuneration chf retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate proposal agm agm agm period period period aggregate aggregate aggregate agm agm agm agm agm agm financial year financial year financial year total aggregate proposal approval total aggregate proposal approval approve agm approve agm exclude legally require employer contribution ahvivalv exclude bonus exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base share price date transfer april approval agm calculation value consideration reduction value block period year reduce market value reconciliation report remuneration comparison ordinary agm submit shareholder approval agm include franz humer bonus chairman shareholder approve remuneration ordinary agm actual remuneration amount member board director chf exclude legally require ordinary agm approve board remuneration employer contribution ahvivalv totalling chf exclude exclude bonus legally require employer contribution ahviv alv exclude bonus period end ordinary agm prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm approval maximum total remuneration approve agm require actual total remuneration pay calculation end period approve limit calculation end period yes exclude legally require employer contribution ahvivalv exclude bonus roche remuneration report remuneration report roche security holding relate party note remuneration corporate director andr hoffmann andreas oeri financial statement roche holding ltd member founder family closely significant shareholder addition executive committee associate belong contractually bind december december shareholder group pool voting right respectively member board director end group hold share person closely associate hold share issue share detailed information nonvoting equity security ne show resolution approval remuneration member group find finance report note table security holding remuneration member corporate corporate executive committee roche group consolidate financial statement executive committee decide remuneration general provision assign authority decision committee discretion take account market corporate executive committee remuneration comparison remuneration committee board security holding share ne director outline page remuneration previous year board decision process approval framework december december director separately submit total aggregate close relative close relative bonuse corporate executive committee member corporate executive security security general meeting financial year committee receive remuneration work share ne holding share ne holding number number numbertype number number number numbertype number retrospectively bind approval show remuneration board ceo severin schwan explain detail director maximum amount total aggregate franz remuneration corporate executive committee hoffmann period ordinary general meeting baschera ordinary general meeting bell table previous year general bulcke meeting prospectively bind approval julius lifton poussot oeri schwan security holding security holding corporate executive committee corporate executive committee voser weder mauro total share hold shareholder group pool voting right list roche remuneration report remuneration report roche high total remuneration pay severin remuneration pay member corporate schwan member corporate executive executive committee include committee total pay corporate executive severin schwan executive member board committee total remuneration pay director receive remuneration primary member corporate executive committee function ceo reflect high total high total remuneration pay severin schwan member corporate executive committee chf base salary ssar rsus restrict stock unit pension fundsmgbinsurance roche connect subtotal bonus subject approval total aggregate bonus corporate executive committee annual general meeting block nonvoting equity securitiesshare psp payment expense allowancefor tax consulting service total calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value include employer contribution social security beneficial part detailed calculation remuneration annual report number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee number rsus grant value chf ne closing price grant date march rsu number rsus grant value chf ne average market price day period prior grant date march rsu stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit share block year calculation number share base share price date transfer april approval agm target number bearer share psp bearer share multiply bearer share price average month october december prior start performance cycle chf bearer share total estimate value annual report year psp award originally target ne award ne total spread relevant period time year value calculate yearend price december chf nonvoting equity security ne psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target ne ne respectively subject change number value ne awardable plan december december respectively spread relevant period time year board director vote actual allocation originally target ne december december respectively accord tsr achieve include annual expense allowance chf payment tax consulting service chf chf additionally employer contribution ahvivalv chf chf pay form compensation detidua base pay chf ayyoubi diggelmann hippe keller oday total include chf loss pension right grant employer contractual agreement detidua base pay member corporate executive committee bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting ayyoubi diggelmann hippe keller oday total detidua bonus member corporate severin schwan members executive committee corporate executive committee receive remuneration committee board director bonus cash payment determined corporate executive committee april severin schwan receive bonus member bonuse base performance form roche share block year agree objective total aggregate bonus payment april bonus bring forward bind vote annual general meeting roche remuneration report remuneration report roche stocksettle stock appreciation right fair value ssar calculate grant ssar member corporate date trinomial model american options executive committee trinomial model effective method ssar show ssar table valuation american option consider introduce roche january possibility exercise option time prior place stock option ssar entitle holder maturity call american option compare benefit financially increase value european option allow exercise roche nonvoting equity security ne maturity date grant date exercise date strike price ssar term multiyear plan number ssar strike price expiry date closing price roche ne grant date grant value ssar show ssar vest year grant date vest ssar table number ssar ssar exercise convert ne calculated time issue enter seven year grant date unexercised ssar value table lapse compensation stocksettle stock appreciation right ssar chf ssar ssar ayyoubi diggelmann hippe keller oday total detidua restrict stock unit rsus number value chf number value chf ayyoubi diggelmann hippe keller oday total calculation value consideration reduction value additional block period year reduce market value calculation value consideration reduction value additional block period year reduce market value calculation value number rsus multiply grant value chf ne closing price grant date march rsu calculation value number rsus multiply grant value chf ne average market price day period prior grant date march rsu information trinomial model american option refer boyle phelim lattice framework option price state variable journal financial quantitative analysis volume issue mar wwwrochecomtrinomial modelpdf strike price table ssar detidua restrict stock unit member remuneration component partially replace ssar corporate executive committee value ssar awards reduce restrict stock unit rsusright receive non balance award form rsus voting equity security threeyear vest period plus value adjustment rsu award allocate individually equivalent sum dividend pay remuneration committee discretion vest period attributable number non vest recipient year vote equity security individual award result nonvoting equity security remain grantedwere introduce new block yearsroche remuneration report remuneration report roche performance share plan psp roche security perform well average tsr roche security ne share rank rsus corporate executive committee member corporate executive committee peer set roche tsr increase compare peer set company operate replace award additional psps member corporate executive committee cycle board director elect industry accord longterm incentive programme member senior management currently increase nes award maximum award term plan participant receive corporate executive committee comprise individual worldwide participate double originallevel reserve target number originally target ne table psp ssar awards performance share plan psp ne accord psp plan start detail psp cycle plus value adjustment future psp award remuneration component psp consist overlap threeyear performance equivalent sum dividend pay calculation psp value correspond reserve corporate executive committee cycle new cycle beginning year vest period attributable number report year newly base fair value enlarge corporate executive committee cycle progress psp nonvoting equity security individual grant bearer share price average psp psp award grant require roche month october december prior start longterm incentive programme psp closed december security perform well performance cycle calculate previous senior management comprise ssar target ne award psp peer set event investment target roche security entire rsu award december target ne award roche security underperform average return psp threeyear cycle distribution year historical psp performance deliver peer company few ne instead calculation award cycle correspond distribution report provision plan number non year cycle disclose target remain voting equity security nes bearer share bearer share reserve plan cycle psp base actual value psp reserve participant cycle member corporate executive committee vest year number security actually award depend show table extent investment roche board director decide actual level security share ne outperform average ne bearer share cash equivalent award performance share plan psp new calculation return investment security issue peer psp cycle set peer company comparison base close financial year respectively fair value grant security market price dividend yield aim psp provide incentive bearer share fair value grant total shareholder return tsr reduce effect participant achieve steady value growth bearer share ne ne price average price average shortterm market fluctuation security price average month october december end psp cycle base month october months october december december prior start performance cycle threemonth average distribute dividend prior fair value prior fair value month october december end totalling chf billion chf billion target number start target number target number start target number bearer share performance cycle bearer share ne psp performance cycle ne psp cycle chf billion chf billion psp psp number value chf value chf number value chf value chf schwan ayyoubi diggelmann hippe keller oday total calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market footnote value detiduaroche remuneration report remuneration report roche performance share plan psp calculation total estimate total estimate award value psp award value psp target number target award target award roche bearer target number number ne number ne share psp ne psp psp psp number number number value chf number value chf schwan ayyoubi diggelmann hippe keller oday total total estimate value psp award originally target ne award exclude value adjustment add nes award spread relevant period time year value calculate yearend price december chf nonvoting equity security plus psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target subject change number value ne awardable plan december spread relevant period time year calculation value nonvoting equity security consideration reduction value block period year reduce market value plus psp estimate value calculate yearend price december chf bearer share base number originally target subject change number value awardable plan december spread relevant period time year calculation value share consideration reduction value block period year reduce market value board director vote actual allocation originally target ne december december respectively accord tsr achieve total estimate value annual report year psp award originally target ne award ne total spread relevant period time year value calculate yearend price december chf nonvoting equity security psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target ne ne respectively subject change number value ne awardable plan december december respectively spread relevant period time year board director vote actual allocation originally target ne december december respectively accord tsr achieve detidua indirect benefit employer contribution chf pension payment pension payment fund annual taxtax fund annual taxtax mgb expense roche consulting mgb expense roche consulting insurance allowance connect service insurance allowance connect service ayyoubi diggelmann hippe keller oday total include employer contribution social security beneficial part indirect benefit member roche connect voluntary stock purchase plan corporate executive committee offer employee opportunity buy roche non employer contribution social security voting equity security ne equal scheme pension plan groupwide employee annual salary discount ne stock purchase plan roche connect respect purchase plan subject hold member corporate executive committee period year switzerland show indirect benefit employer contribution table employer contribution addition member corporate executive show table committee receive annual expense allowance member payment foreign tax obligation tax consulting service show table detidua remuneration loan member remuneration member corporate executive committee corporate executive committee base contractual obligation roche pension totalling chf paidto individual member corporate executive chf pay corporate committee children school cost executive committee member totalling chf chf total remuneration pay member aforementione additional payment corporate executive committee include total remuneration member calendar year member corporate executive committee corporate executive committee receive remuneration include bonus total chf loan credit grant chf exclude additional employer member corporate executive committee contribution pay ahvivalv totalling chf chf maximum regular period notice member form compensation corporate executive committee month changeofcontrol clause employment contract mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit detidua detidua detidua detidua roche pay legally require employer contribution member corporate executive committee total chf chf swiss legally require contribution separately social security programme provide retirement state ceo disability unemployment benefit ahvivalvroche remuneration report remuneration report roche additional remuneration bonus severin schwan form roche share prospective approval member executive committee total future aggregate remuneration chf mention payment pay current block year member member corporate executive committee corporate executive committee cash proposal agm agm agm payment totalling chf respect aggregate aggregate aggregate executive remuneration subject approval financial year chf period period period annual general meeting exclude legally require employer contribution agm agm agm agm agm agm ahvivalv submit propose total total aggregate proposal approval submission executive total aggregate ordinary annual general meeting approve agm bonus bind vote annual general agm bind vote exclude legally require employer contribution ahvivalv exclude bonus meet board director propose award member corporate executive committee reconciliation report remuneration exclude bonus period end shareholder prospectively approve ordinary agm remuneration member corporate retrospective approval member executive committee total aggregate bonus chf executive committee comparison ordinary agm ordinary ordinary agm approve remuneration agm remuneration amount chf proposal agm agm agm corporate executive committee totalling exclude legally require employer contribution aggregate aggregate aggregate chf exclude legally require ahvivalv exclude bonus psp assumption financial year financial year financial year employer contribution ahvivalv maximum value total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv prospectively approve total remuneration member executive committee comparison total remuneration chf submission executive total future executive total future aggregate total remuneration total remuneration total remuneration aggregate remuneration bind shareholder remuneration compose base pay longterm period period period vote incentive ssar calculate grant value agm agm agm agm agm agm board director propose consider reduction value block approval ordinary agm approve remuneration period applicable psp calculate time maximum total remuneration approve agm require corporate executive committee totalling reservation nonvoting equity security share total remuneration calculation end period chf exclude legally require take account maximal potential approve limit yesno calculation end period yes employer contribution ahvivalv double contribution pension benefit exclude additional pay new member exclude bonus period end legally require employer contribution ahviv corporate executive committee approval ordinary agm alv contribution expense payment agm approved total tax consulting service roche connect exclude legally require employer contribution ahvivalv exclude bonus roche remuneration report remuneration report roche clawback accord regulation psp programme share nonvoting equity security ne addition applicable statutory provision roche originally target award ne share december december longterm incentive plan include option partially shall lapse compensation notice close relative close relative reclaim distribute compensation result special termination employment give reason share ne security holding share ne security holding circumstance clawback redundancy disability retirement number number numbertype number number numbertype corporate employee voluntarily serve notice termination guideline security holding executive employment ssar rsus unvested board director decide ceo committee date termination employment lapse cec member acquire share andor schwan immediately compensation ne equivalent annual base salary ceo ayyoubi annual base salary respectively end diggelmann termination employment result retain holding long serve hippe misconduct ssar rsus grant cec exception roland diggelmann keller share share outstanding vest unvested shall lapse member corporate executive committee oday immediately compensation accord fulfil requirement total share share ssar plan rule misconduct participant include inter alia security holding activity lead disciplinary action december december repeat willful failure perform duty respectively member cec person reasonably assign roche closely associate hold security violation law public regulation show table share nonvoting equity commission crime security ne ssar restrict stock unit gross negligence willful misconduct rsus employment engage conduct bring disgrace disrepute roche andor subsidiary violation roche directive guideline relate business conduct type security value acquire ceo share andor nes annual base salary member corporate executive committee share andor nes annual base salary detiduaroche remuneration report remuneration report roche detidua detidua ssar restrict stock unit rsus number ssar hold december number rsus hold december corporate executive corporate executive committee committee schwan schwan ayyoubi ayyoubi diggelmann diggelmann hippe hippe keller keller oday oday total total grant value rsu chf chf chf price chf ne closing price grant ne average market price ne average market price date march day period prior grant date day period prior grant date market price nes march march december chf expiry date grant value ssar chf trinomial model american option alue accord correspond annual report option hold position option show table issue roche employee stock option option entitle holder purchase roche nonvoting equity security ne term multiyear option plan strike price option show closing price roche ne grant date option show nontradable option subject vest period year vest period year vest period year unvested option lapse compensation employment terminate voluntarily reason retirement vest option exercise limited period timeroche report statutory auditor report statutory auditor roche report statutory auditor apply value component remuneration assess overall presentation remuneration report general meeting roche holding ltd believe audit evidence obtain basel sufficient appropriate provide basis opinion opinion audit accompany remuneration auditor responsibility opinion remuneration report report date january roche holding ltd responsibility express opinion year end december roche holding ltd year end december audit accompany remuneration report conduct complie swiss law article limited information accord article audit accordance swiss auditing ordinance ordinance excessive compensation standard standard require comply stock exchange list company ordinance ethical requirement plan perform contain section mark blue line audit obtain reasonable assurance include respective footnote page remuneration report complie swiss law remuneration report article ordinance kpmg responsibility board director audit involve perform procedure obtain board director responsible audit evidence disclosure preparation overall fair presentation remuneration report regard compensation remuneration report accordance swiss law loan credit accordance article ordinance excessive compensation ordinance procedure select depend stock exchange list company board auditor judgement include assessment director responsible design risk material misstatement remuneration ian starkey marc ziegler remuneration system define individual report fraud error audit license audit expert license audit expert remuneration package include evaluate reasonableness method auditor charge basel january roche independent assurance report independent assurance report roche procedure perform response assess risk process determination impact stakeholder peer consequently nature timing extent procedure competition review integration relevant regulatory gathering sufficient appropriate evidence deliberately requirement integration key organisational value limit relative reasonable assurance engagement objective report prioritisation material aspect assurance obtain limited assurance inspect integration sustainability risk independent assurance report engagement reasonable assurance engagement opportunity group risk management process adherence internal guideline procedure select depend assurance practitioner assessment process data consolidation roche sustainability report judgement review management ofand sustainability reporting process contribution people key figure independence quality control assess consolidation process datum roche corporate governance sustainability committee environmental protection report guideline publish comply independence ethical group level roche hold basel roche european chemical industry council cefic requirements code ethic professional sustainability report guideline publish accountant issue international ethic standard carry work datum report prior engage perform assurance procedure global reporting initiative gri board accountant found fundamental reporting period perform work respect provide limited assurance aspect roche group internal corporate reporting manual principle integrity objectivity professional competence projection target conduct work sustainability report roche include annual version group report manualsustainability care confidentiality professional behaviour datum outline subject matter define report report report firm apply international standard quality control roche materiality determination process base accordingly maintain comprehensive system quality believe evidence obtain sufficient scope subject matter sustainability report guideline publish control include document policy procedure appropriate provide basis assurance conclusion limited assurance engagement focus follow global reporting initiative gri compliance ethical requirement professional datum information disclose sustainability report define guideline people standard applicable legal regulatory requirement conclusion roche consolidate subsidiary year end contribution key figure sustainability risk base work perform describe report december opportunity internally gather collate summary work perform identify sustainability report management reporting process respect aggregate assurance procedure include come attention cause believe sustainability report material aspect accuracy completeness sustainability indicator follow work material respect preparation safety security health environmental subject inherent limitation give nature method evaluation application roche group guideline roche group internal sustainability report guideline protection people key figure related determine calculate estimate datum review application roche group internal base gri sustainability report guideline control environment relation datum aggregation assurance report read connection corporate sustainability contribution guideline cefic guideline apply key figure roche internal guideline definition procedure site visit management inquiry internal reporting process collect aggregate key figure include greenhouse gas emission report sustainability performance visit select site roche pharmaceutical people datum function design provide scope scope result business travel diagnostic division usa canada appropriate basis disclosure compress air liquid nitrogen table graph responsibility methodology china selection base quantitative internal reporting process collect aggregate page people key figure disclose roche corporate governance sustainability qualitative criterion contribution datum function design page report committee responsible subject matter interview personnel responsible internal sustainability provide appropriate basis disclosure consolidated datum information roche group criterion selection preparation presentation report data collection site visit roche materiality determination process disclose level relation contribution breakdown disclose select information accordance criterion roche group level determine understand adhere principle guide factor report responsibility form independent opinion base application roches internal sustainability guideline soundness stakeholder determination peer review relevance materiality determination process roche group level limited assurance procedure assessment key figure regulatory environment integration key organisational according requirement gri guideline come attention indicate identify perform test sample basis evidence support value objective define gri disclose page report sustainability information select contain report select contribution people key figure design sustainability risk opportunitie design sustainability risk opportunity state material respect accordance roche accident rate energy consumption greenhouse gas determination process corporate level disclose determination process base roche corporatelevel reporting criterion emission relate energy consumption halogenate function design activity disclose paragraph assess hydrocarbon water waste contribution healthcare sustainability information mention subject sustainability risk opportunity report plan perform procedure accordance institution patient organization public policy body matter disclose sustainability report people key figure disclose roche website international standard assurance engagement isae philanthropic organization headcountfte datum roche annual report reference section nonfinancial reporting subsection revise assurance engagement audits training hour concern completeness accuracy section webpage state accordance value employee review historical financial information standard adequacy consistency reporting criterion require comply ethical requirement plan inspection documentation analysis relevant criterion perform assurance engagement obtain limited assurance policy principle zurich january management reporting process respect identify sustainability information inspect relevant documentation sample basis pricewaterhousecooper sustainability report key figure assess include roche group sustainability policy management internal policy procedure set forth limited assurance engagement isae revise reporting structure documentation follow substantially scope reasonable assurance inspect principle roche materiality process roche group internal sustainability report guideline engagement relation risk assessment procedure provide definition development adherence base responsible care health safety include understand internal control gris environmental social economic reporting requirement address soundness identification christophe bourgoin bettina buomberger roche imprint imprint roche publish cautionary statement forwardlooke hoffmannla roche ltd statements group communications annual report contain certain forward basel switzerland look statement forwardlooke statement tel identify word believe expect wwwrochecom anticipate project intend seek estimate future similar expression order publication discussion thing strategy goal tel plan intention factor cause actual fax result differ materially future email baselwebmasterrochecom reflect forwardlooke statement contain annual report price medium relation product initiative competitor legislative tel regulatory development economic condition statement earning share growth roche annual report publish german email rochemediarelationsrochecom delay inability obtain regulatory approval profit forecast interpret english bring product market fluctuation mean roche earning earning share investor relation currency exchange rate general financial subsequent period necessarily match report consist actual annual report tel market condition uncertainty discovery exceed historical publish earning finance report contain email investorrelationsrochecom development marketing new product new earning share roche annual report annual financial statement use exist product include limitation consolidate financial statement corporate sustainability committee negative result clinical trial research project trademark mention enjoy legal protection article incorporation sense tel unexpected effect pipeline market management reporting email corporatesustainabilityrochecom product increase government pricing pressure link thirdparty page provide interruption production loss inability convenience express opinion print nonchlorine bleach fsccertified paper annual general meeting obtain adequate protection intellectual property content thirdparty page expressly march right litigation loss key executive disclaim liability thirdparty information communication employee adverse publicity use news coverage believe urgent deliver medical solution right noweven develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rochefhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche annual report aannnnuuaall rreeppoorrtt improve diagnostic keep pace emerge help drive innovation new advance medicine important market growth meet goal collaboration strate pipeline news include clearance increase representation gic partnership establish molecular pointofcare people establish foundation medicine provide strep test positive latestage develop region experience new possibility study result multiple sclerosis key leadership role prove patient care